Benzodiazepines in the Management of Seizures and Status Epilepticus: A Review of Routes of Delivery, Pharmacokinetics, Efficacy, and Tolerability

Ricardo Kienitz1,2 · Lara Kay1,2 · Isabelle Beuchat1,2,3 · Sarah Gelhard1 · Sophie von Brauchitsch1 · Catrin Mann1,2 · Alexandra Lucaci1 · Jan-Hendrik Schäfer1 · Kai Siebenbrodt1,2 · Johann-Philipp Zöllner1,2 · Susanne Schubert-Bast1,2,4 · Felix Rosenow1,2 · Adam Strzelczyk1,2 · Laurent M. Willems1,2

Accepted: 11 July 2022 / Published online: 16 August 2022 © The Author(s) 2022

Abstract
Status epilepticus (SE) is an acute, life-threatening medical condition that requires immediate, effective therapy. Therefore, the acute care of prolonged seizures and SE is a constant challenge for healthcare professionals, in both the pre-hospital and the in-hospital settings. Benzodiazepines (BZDs) are the first-line treatment for SE worldwide due to their efficacy, tolerability, and rapid onset of action. Although all BZDs act as allosteric modulators at the inhibitory gamma-aminobutyric acid (GABA)A receptor, the individual agents have different efficacy profiles and pharmacokinetic and pharmacodynamic properties, some of which differ significantly. The conventional BZDs clonazepam, diazepam, lorazepam and midazolam differ mainly in their durations of action and available routes of administration. In addition to the common intravenous, intramuscular and rectal administrations that have long been established in the acute treatment of SE, other administration routes for BZDs—such as intranasal administration—have been developed in recent years, with some preparations already commercially available. Most recently, the intrapulmonary administration of BZDs via an inhaler has been investigated. This narrative review provides an overview of the current knowledge on the efficacy and tolerability of different BZDs, with a focus on different routes of administration and therapeutic specificities for different patient groups, and offers an outlook on potential future drug developments for the treatment of prolonged seizures and SE.

Adam Strzelczyk and Laurent M. Willems contributed equally.

Adam Strzelczyk
strzelczyk@med.uni-frankfurt.de

1 Epilepsy Center Frankfurt Rhine-Main and Department of Neurology, Center of Neurology and Neurosurgery, Goethe-University Frankfurt, Schleusenweg 2-16, 60528 Frankfurt am Main, Germany
2 LOEWE Center for Personalized Translational Epilepsy Research (CePTER), Goethe-University Frankfurt, Frankfurt am Main, Germany
3 Département des neurosciences cliniques, Centre hospitalier universitaire Vaudois, Lausanne University Hospital, Lausanne, Switzerland
4 Department of Neuropaediatrics, Goethe-University Frankfurt, Frankfurt am Main, Germany
Benzodiazepines in the management of seizures and status epilepticus: a review of routes of delivery, pharmacokinetics, efficacy, and tolerability

doi: 10.1007/s40263-022-00940-2

Ricardo Kienitz, Lara Kay, Isabelle Beuchat, Sarah Gelhard, Sophie von Brauchitsch, Carin Mann, Alexandra Lucaci, Jan-Hendrik Schafer, Kai Siebenbrodt, Johann-Philipp Zöllner, Susanne Schubert-Bast, Felix Rosenow, Adam Strzelczyk*, Laurent M. Willems*

CNS Drugs

**Route of delivery**

- **Intravenous**
  - Clonazepam
  - Diazepam
  - Lorazepam
  - Midazolam
  - Gold standard if PVC established
  - Restricted to medical professionals

- **Nasal**
  - Diazepam
  - Lorazepam
  - Midazolam
  - Feasible option if PVC is not yet established
  - Easy to use for medical non-professionals

- **Intramuscular**
  - Diazepam
  - Lorazepam
  - Midazolam
  - Feasible option if PVC is not yet established
  - Autoinjectors available for non-professionals

- **Rectal**
  - Lorazepam
  - Midazolam
  - Feasible option for seizure clusters or in palliative care settings
  - Easy to use for medical non-professionals

- **Oral**
  - Diazepam
  - Clonazepam
  - Lorazepam
  - Midazolam
  - Inadequate route for treatment of status epilepticus
  - Difficult to handle, may cause discomfort

**Available benzodiazepines**

- Clonazepam
- Diazepam
- Lorazepam
- Midazolam

**Time till cessation**

- 5 min
- 5-15 min
- 5-45 min
- >30 min
- >45 min
- >60 min

PVC = peripheral venous catheter, i.v. = intravenous, i.m. = intramuscular, i.n. = intranasal

* contributed equally, † availability may differ depending on country

This graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, please see the full text online. © The authors, CC-BY-NC 2022.
**Key Points**

- Non-intravenous routes for the delivery of benzodiazepines are becoming increasingly important in pre-hospital and in-hospital settings.
- Ready-to-use nasal sprays, syringes, rectioles or autoinjectors are particularly suitable for lay use by epilepsy patients or their caregivers.
- Somnolence is frequently reported after benzodiazepine administration, while severe side effects, such as respiratory depression and hypoxia, are rare.
- The choice of benzodiazepine depends amongst others on individual pharmacokinetic and pharmacodynamic characteristics and available routes of administration.

## 1 Introduction

The emergency treatment of prolonged epileptic seizures, seizure clusters and status epilepticus (SE) is required to be rapid and efficient, as ongoing epileptic activity may lead to neuronal damage and result in increased morbidity and mortality [1–3]. The ideal anticonvulsant agent for this purpose should be safe, easy to administer, and exhibit a long-lasting anti-seizure effect without relevant side effects. The delineation between prolonged epileptic seizures, seizure clusters and SE is—to some extent—arbitrary and has evolved over the last few decades; however, any rescue medication should prevent seizure recurrence as well as the progression of a seizure or a series of seizures into SE [1, 4].

Benzodiazepines (BZDs), such as lorazepam (LZP), midazolam (MDZ), diazepam (DZP) and clonazepam (CZP), are established first-line drugs for the acute treatment of seizures [5]. BZDs are a family of drugs that exert their effects by allosterically modulating the activity of the ionotropic gamma-aminobutyric acid (GABA)-A receptor in the central nervous system (CNS). These drugs increase the probability that GABA binding to the receptor will open the associated Cl⁻ channel. Thus, these drugs generally decrease neuronal excitation and exhibit antiseizure, sedative-hypnotic, anxiolytic, muscle relaxant and amnesic properties. As a side effect, BZDs can cause drug dependence, mostly due to recreational misuse or long-term intake against medical advice, cognitive impairment and—when administered in higher doses—can cause respiratory depression.

Available routes of delivery for these drugs include intravenous (i.v.), oral (p.o.), rectal (r.s.), intramuscular (i.m.), buccal, intranasal (i.n.), and even intraosseous [6–10]. Difficulties with achieving i.v. access may lead to a delay in drug administration, rendering the development of alternative suitable routes vital, as responsiveness to BZDs during seizures decays over time [11]. Jaw clenching, hypersalivation and uncontrollable swallowing are major limitations inherent to the p.o. and buccal routes [12], making it difficult to minimize variability in pharmacodynamics due to variable intake [13]. Intramuscular injections can also be challenging in patients with tonic–clonic or hypermotor seizures [7]. While r.s. administration might be hindered by generalized convulsions, it is also becoming less popular due to the social distress and sense of shame it imposes on both patients and caregivers [14].

In comparison, i.n. administration may be a more favorable option, as it can be administered in a significantly shorter amount of time without the need for an i.v. route, and may be preferred by caregivers compared to the r.s. route [15]. Recently approved commercial preparations of MDZ and DZP nasal sprays have become available for the treatment of seizures, clusters, and there is growing evidence supporting the use of pharmacy-manufactured MDZ preparations for seizures and SE. However, the use in SE is not yet established.

In this review, we discuss the commonly used BZDs, with a focus on their pharmacodynamics, pharmacokinetics, metabolism and available formulations, and we summarize the published data on their efficacy, safety and routes of delivery in the clinical management of seizures, seizure clusters and SE.

### 1.1 Status Epilepticus and Seizure Clusters

In 2015, the International League Against Epilepsy published a report on the definition and classification of SE [16]. This SE definition sets two time points (t1, t2), where t1 defines the semiological transition of a seizure to SE and t2 marks the point in time when neurological injury is likely to occur. Typically, the start of SE treatment is based on t1, with the time limit being 5 min for generalized convulsive (tonic–clonic) SE, 10 min for complex focal SE (focal SE with impaired consciousness), and 10–15 min for absence SE [16]. This definition applies to ongoing seizures or a series of discrete seizures between which there is only incomplete recovery of the previous neurological status. SE-induced neuronal damage is assumed to occur later, after a time (t2) of 30 min with generalized convulsive SE (GCSE) and after 60 min with complex focal SE [16]. The 5-min time limit that usually marks the transition from a prolonged seizure to SE dates back to an operational definition proposed by Lowenstein in 1999, aimed at ensuring that patients receive treatment as soon as possible [17]. This approach—equaling seizures longer than 5 min and SE irrespective of
seizure semiology—was amongst others adopted by the German clinical practice guidelines on SE [18].

Using a variety of different methodologies, regions and populations, the incidence of SE has been estimated to be 10–41 per 100,000. The overall mortality rate is 13%, but can reach up to 40% in a super-refractory course of SE [1, 19, 20]. Clinical and experimental data show a correlation between a delayed start of treatment and the reduced likelihood of successful SE termination with the first treatment attempt [11, 21, 22]. Potential underdosing might play a further role in this context [23, 24]. The urgency with which to begin treatment depends on the SE type and appears to be most pressing with GCSE [25].

The clustering of seizures in turn is a common clinical phenomenon and describes an increase in seizure frequency during a specific period of time, where the probability of seizure occurrence is affected by the occurrence of a previous seizure [26]. A recent review found the prevalence of seizure clusters to be between 13 and 76% for outpatient studies and 18% and 61% for inpatient video-EEG monitoring studies likely involving a high percentage of therapy-resistant epilepsy [26], while a cohort study using the United Kingdom General Practice Research Database estimated the age-adjusted prevalence at 2.5/10,000, with a peak in the 0–4 years age group (5.9/10,000) [27]. Despite being a common phenomenon, seizure clusters still lack a clear definition. Previous studies looking into acute treatment (with DZP) defined them as a characteristic episode of multiple complex partial or generalized convulsive seizures occurring within a 24-h period in adults or a 12-h period in children, with a pattern distinguishable from the patient’s usual seizure pattern, and with an onset readily recognizable by a caregiver that will predict further seizures [28, 29]. Other studies have used a minimum number of seizures as a criterion (e.g., at least three seizures within 24 h, or within 4 h during video-EEG monitoring) [30–32].

While the mechanisms leading to seizure clusters are not yet well understood, well-described catamennial phenomena (i.e., a worsening of seizures in relation to the menstrual cycle) may result in perimenstrual seizure clusters [33, 34]. A better understanding of the prediction, occurrence and clustering of seizures will likely result from big data approaches, which may help to better define the clinical course and dynamics of seizure clusters [35, 36].

2 Characteristics of Individual Benzodiazepines

In the following sections we discuss the characteristics of the most commonly used individual benzodiazepines—lorazepam, midazolam, diazepam and clonazepam.

2.1 Lorazepam

LZP is a BZD with a fast onset of anticonvulsant action: It begins to act about 1–3 min after i.v. injection and has a short-to-intermediate duration of action. Additionally, LZP has sedative-hypnotic and anti-anxiety effects. Common doses for the treatment of SE in adults are 2–4 mg in the pre-hospital phase [37]. The American Epilepsy Society recommends a LZP dose of 0.1 mg/kg (a maximum single dose of 4 mg), which may be repeated [38]. In adults and children, i.v. LZP is established as efficacious at stopping seizures lasting at least 5 min [38], but due to the faster time for administration, i.m. MDZ has superior effectiveness in adults with convulsive SE when an i.v. access is not established [38].

2.1.1 Pharmacodynamics, Pharmacokinetics and Metabolism

LZP is readily absorbed after sublingual, p.o. and i.m. administration, and the bioavailability for all routes of administration exceeds 94%. The preferential route of administration for seizures or SE, however, is i.v. injection, as peak plasma concentrations are reached significantly slower when using other routes (at least 1 h after p.o. or sublingual use) [39]. LZP is highly bound to plasma proteins (91%) [40] and only unbound drug fraction diffuses into the CNS. LZP remains mostly in the intravascular compartment, as its lipophilicity is lower than that of DZP and the volume of distribution (Vd) is thus comparatively low (1.3 L/kg body weight) [39, 40]. This leads to prolonged clinical effects of LZP after a single dose by a rebalancing of bound and free drug fractions, even though “paradoxically” the elimination half-life is shorter than that of DZP [41]. A slower redistribution from the CNS to other tissues due to its relatively lower lipophilicity than, for example, DZP might further contribute to the prolonged clinical effect. This also means that LZP does not significantly accumulate in body fat after repeated administrations. Hepatic one-step, non-oxidative conjugation at the 3-hydroxy group to LZP-glucuronide is rapid, after which this non-active metabolite is predominantly excreted renally [42]. The duration of action is about 10–20 h and the elimination half-life is 8–25 h [39, 40].

2.1.2 Available Formulations

LZP is available as a tablet (0.5 mg, 1 mg and 2 mg tablets) or a concentrate (2 mg/ml) for oral use, and as a solution for i.v. injection (2 mg/ml and 4 mg/ml). In Canada and Europe, a sublingual tablet is also available (0.5 mg, 1 mg and 2.5 mg tablets). In the setting of comfort care, LZP may be used subcutaneously or rectally, but this is off-label. There is currently no manufactured form of LZP for
i.n. administration. There is some evidence that it might be efficacious in SE termination, at least in children [43]. However, nasal administration is off-label.

### 2.1.3 Clinical Efficacy

Before the US Food and Drug Administration (FDA) approved LZP on 30 September 1977, in 1975 a phase II trial of i.v. LZP showed promising results controlling seizures in 11 patients with EEG-confirmed SE [44]. Soon after the market introduction of LZP, Walker et al. [45] performed a non-randomized prospective trial in patients with SE, resulting in a seizure control rate of 88%. The first randomized, double-blind trial, which was designed to compare the efficacy of LZP and DZP, was published in 1983 [46] and demonstrated a higher percentage of seizure control with LZP compared to i.v. DZP. Pivotal results came from the first randomized and double-blind trial by Treiman et al. [47] in 1988, which demonstrated a superior efficacy of LZP over phenobarbital (PB) and at least equal efficacy to phenytoin (PHT ± DZP) as a first-line treatment for SE. Subsequently, further trials were designed to study the benefits of outpatient administration of LZP. Alldredge et al. [22] conducted a large placebo-controlled trial, showing that LZP at a dose of 2 mg led to seizure termination more frequently than placebo or DZP following i.v. administration by trained emergency medical technicians. However, in the largest preclinical trial to date, Silbergleit et al. [48] found that, in comparison to i.m. MDZ, the i.v. administration of LZP is more time-consuming due to venous access placement, resulting in inferiority despite high response rates in both groups. Another drawback of LZP is the need for refrigeration, limiting its use in ambulances. In the paediatric setting, LZP has been compared in controlled trials with DZP, demonstrating equal [49, 50] or higher efficacy [51]. Compared to i.m. MDZ, i.v. LZP showed a similar rate of seizure cessation [52]; albeit, this particular randomized trial was underpowered and was based on a re-analysis of [48].

In sum, LZP is frequently singled out among the BZDs for its rapid onset of action and effective seizure control when used as a first-line treatment for SE and given i.v. in adequate dose. It should be noted that, due to concerns for respiratory depression, the administration of insufficient doses with resulting limitations in efficacy is quite common. While the guidelines recommend a dose of 0.05–0.1 mg/kg [38], a prospective study of adult patients with SE demonstrated that a lower dose was administered in 84–95% of cases [53].

Tables 1 provide a detailed overview of the studies discussed in this section.

### 2.2 Midazolam

MDZ has a relatively short half-life of only 1–4 h. This drug exhibits anticonvulsant, sedative-hypnotic, anxiolytic, muscle relaxant and amnesic properties [54]. Following its first FDA approval in 1985, MDZ was mainly used to promote preoperative sedation, anxiolysis and anesthesia induction. More recently, newer forms of administration have extended its use to treating prolonged seizures, seizure clusters and SE. In contrast to other BZDs, MDZ formulations are available with a wide range of administration routes including p.o. (tablet and syrup), i.v., i.m., r.s., buccal and i.n. However, officially approved indications vary across the administration routes.

#### 2.2.1 Pharmacodynamics, Pharmacokinetics

and Metabolism

MDZ is generally readily absorbed after administration. However, the exact time to peak plasma concentrations (T_{max}) and bioavailability differ significantly between administration routes (p.o.: 1–2 h, 40–50%; i.v. < 5 min; i.m.: 45 min, > 90%; r.s.: 30 min, 50% (off-label); buccal: 30 min, 75%; i.n.: 7–15 min, 44%) [55–62]. When comparing to i.v. administration, i.n. administration reaches maximal plasma concentrations only slightly slower with lower maximal plasma levels. At a physiological pH, MDZ is bound to plasma proteins (97%) in part due to its lipophilia; however, at a lower pH, it becomes hydrophilic, allowing for water-based solutions. MDZ crosses the placenta and is also excreted into human milk [61]. Compared to other BZDs, MDZ has a rather short half-life of 1.5–3.5 h [63]. This drug is primarily metabolized in the liver by cytochrome P450 3A4 (CYP3A4), and its metabolites, mainly 1-hydroxymidazolam, are excreted in the urine [63]. MDZ, like other BZDs, may potentiate the action of other CNS depressants and alcohol.

#### 2.2.2 Available Formulations

MDZ is available as a tablet (7.5 mg/tablet) or syrup (2 mg/ml) for p.o. use in adult and paediatric patients, respectively, mainly for sedation, anxiolysis and amnesia prior to diagnostic, therapeutic or endoscopic procedures, or before anesthesia induction. A solution for i.v. injection (1 mg/ml, 5 mg/ml) is available for promoting preoperative sedation, anxiolysis, anesthesia induction or amnesia. A solution for i.m. injection (5 mg/ml) is approved for the treatment of SE in adults. Rectal use has also been reported in several studies but is not officially approved. In 2019, MDZ was approved as a nasal spray (Nayzilam®) by the FDA for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, repetitive seizures) that are
Table 1  Summary of studies on the use of lorazepam for status epilepticus

| Delivery route | Study design | n   | Age (years) | SE types | Dosage (mg) | Seizure control (%) | TEAE rate (%) | Frequent TEAE (%) |
|---------------|-------------|-----|-------------|----------|-------------|---------------------|---------------|------------------|
| Intravenous   |             |     |             |          |             |                     |               |                  |
| LZP           | OLS, SC     | 11  | ≥ 6         | SE       | 2.5–5       | 100                | –             | –                | [44]             |
| LZP           | OLS, SC     | 25  | 5–81        | SE, RS   | 4–8         | 88                 | 12            | Respiratory depression (4) |
| LZP           | OLS, SC     | 9   | 16–60       | SE       | 4           | 88                 | –             | –                | [191]            |
| LZP           | OLS, SC     | 31  | 2–18        | SE       | 0.05–0.1^a  | 81                 | 0             | –                | [192]            |
| LZP           | OLS, SC     | 77  | < 12        | SE       | 0.1^a       | 79                 | –             | –                | [193]            |
| LZP vs. i.v. CZP | OLS         | 61  | ≥ 18        | SE       | 4–10        | 51–63               | 100           | Drowsiness (100)/psychomotor agitation (12) |
| LZP vs. i.v. DZP | RCT, DB, SC | 78  | ≥ 18        | SE       | 4           | 89                 | 13            | Respiratory depression |
| LZP vs. i.v. DZP | ReS, SC     | 44  | 0–18        | SE, RS   | 0.03–0.22^b | 82                 | 25            | Respiratory depression |
| LZP vs. i.v. DZP | RCT, DB, MC | 273 | 0.25–17     | CSE      | 0.1^a       | 72.9               | –             | Sedation (67)/respiratory depression (37) |
| LZP vs. i.v. DZP | RCT, OLS, SC | 48  | 1–11        | CSE      | 0.13^a      | 65                 | 19            | Admission to ICU |
| LZP vs. i.v. LEV | RCT, OLS   | 79  | 1–75        | CSE, NCSE, RS | 0.1^a | 75.6               | –             | –                | [195]            |
| LZP vs. i.v. DZP vs. i.v. placebo | RCT, DB, SC | 205 | ≥ 18        | SE, RS   | 2 (LZP) 5 (DZP) | 59                 | 11            | Respiratory depression |
| LZP vs. i.v. DZP + PHT | RCT, OLS, SC | 178 | 1–12        | CSE      | 0.1^a       | 100                | 4             | Respiratory depression |
| LZP vs. i.v. MDZ vs. i.v. CZP | PS, MC     | 177 | ≥ 16        | SE, RSE  | 0.1^a       | Inferior to CZP or MDZ | –             | –                | [53]             |
| LZP vs. i.v. DZP + PHT vs. i.v. PHT vs. i.v. PB | RCT, DB, MC | 384 | 58.6 ± 15.6 (CSE) 62 ± 15.1 (NCSE) | CSE, NCSE | 0.1^a | 65                 | –             | Hypotension (26)/respiratory depression (10)/cardiac arrhythmia (7) |
| LZP (i.v. and rectal) vs. i.v. DZP | PS, RCT, OLS, SC | 102 | < 18        | S, RS, SE | –           | 76                 | 3             | Respiratory depression |
| LZP vs. rectal DZP | PS, MC     | 182 | 0.2–16      | CSE      | 0.1^a       | Superior to DZP    | –             | –                | [196]            |
| LZP vs. i.m. MDZ | RCT, DB, MC | 893 | 1–94        | SE       | 4           | 63.4               | –             | Respiratory depression (14)/hypotension (14) |
| LZP vs. i.m. MDZ | Secondary analysis | 120 | < 18        | SE       | 4–10        | 71.6               | –             | –                | [52]             |

RCT randomized controlled trial, OLS open-label study, SC single-centre, MC multicentre, DB double-blind, PS prospective study, ReS retrospective study, CO cross-over, HV healthy volunteer, S seizure, RS repetitive seizure, SE status epilepticus, RSE refractory status epilepticus, TEAE treatment-emergent adverse event, i.v. intravenous, i.n. intranasal, i.m. intramuscular, p.o. oral, s.l. sublingual, MDZ midazolam, LZP lorazepam, CZP clonazepam, DZP diazepam, PHT phenytoin, CBZ carbamazepine

^a Milligram per kilogram body weight (mg/kg BW)
distinct from a patient’s usual seizure pattern in patients with epilepsy 12 years of age and older [64, 65]. Nayzilam® is licensed for administration by a non-healthcare professional in patients actively seizing when and where a seizure cluster occurs. Intranasal MDZ solutions can also be formulated by pharmacies [66–68].

In Europe, MDZ is also European Medicines Agency (EMA) approved for buccal use (Buccolam®, oromucosal solution: 2.5 mg/0.5 ml, 5 mg/1 ml, 7.5 mg/1.5 ml, 10 mg/2 ml) for the treatment of prolonged, convulsive seizures in infants, toddlers, children and adolescents (from 3 months to < 18 years). The reason for the exclusive paediatric-use marketing authorization is that it is a special approval procedure. Thus, only i.m., buccal and i.n. administrations are officially approved for the treatment of seizures.

2.2.3 Clinical Efficacy

Due to a long history of approval, the release of MDZ in 1985, and the different approval modalities for drugs at that time, there are no phase I or II clinical trials on the i.v. use of MDZ. There are, however, several studies that have assessed the efficacy of i.v. MDZ as a bolus dose followed by a continuous infusion to terminate refractory SE (RSE) [69–71]. More recent studies have focused on other routes of administration, including i.m., buccal and i.n. Regarding i.m. administration, the first evidence stems from 1992 when Chamberlain et al. [72] showed that children with prolonged motor seizures received medication sooner and had a faster cessation of seizures when administered i.m. MDZ compared to i.v. DZP. It was subsequently shown that MDZ is also effective in terminating SE (in combination with oral PHT or carbamazepine [CBZ]) [73]. More recently, it was reported that i.m. MDZ is not inferior to i.v. LZP with regard to prehospital SE [48], which was followed up by studies showing that i.m. MDZ can act faster than r.s. DZP [74] in terminating motor activity during SE in children, and that fewer children receiving i.m. MDZ had recurrent seizures, were intubated or required ICU care compared to i.v. LZP [52].

In 1999, it was also shown that the buccal administration of MDZ is at least as effective as r.s. DZP in terminating prolonged seizures in children and young adults [75]. In addition, buccal MDZ is effective in terminating prolonged seizures in children [76] and can terminate serial seizures or SE faster and with fewer adverse events than r.s. DZP in adults [77].

The latest MDZ formulation is a nasal spray. It has been shown that i.n. MDZ reaches dose-dependent maximal plasma concentrations after ~8–14 min, with sneezing and local irritation reported as the most common side effects [58, 78]. Two recent phase III studies have assessed the efficacy of 5–10 mg i.n. MDZ to terminate seizures and showed the drug to be effective in approximately 54% of seizure clusters within 10 min (placebo response rate 34%) [79, 80]. Intranasal administration of MDZ has also been compared to DZP and it was found that i.n. MDZ was equally as effective as i.v. DZP in controlling seizures in children [81]. While the treatment was initiated faster in the MDZ group, the seizures were controlled slightly faster with i.v. DZP when the time needed to establish an i.v. line was excluded. Subsequent studies showed that i.n. MDZ resulted in a faster onset of action and a faster termination of seizures compared to i.v. DZP in prolonged (febrile) seizures in children [15, 82]. Two additional studies showed no significant differences in efficacy between i.n. MDZ and r.s. DZP for terminating prolonged seizures in both adults [83] and children [14] when administered by caregivers. Importantly, i.n. MDZ was generally preferred by caregivers and patients over r.s. DZP in these settings due to the ease of administration. A retrospective study showed that i.n. MDZ was comparable to i.v. LZP for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit [84]. Use of i.n. MDZ for the treatment of SE was demonstrated in a open-label pharmaco-EEG study showing SE termination in 57% of the cases at an average time of 5 min [66].

Open questions include whether i.n. MDZ can reduce the transformation of seizures into a status epilepticus, the number of applications without increasing adverse events, and whether the availability of MDZ spray increases the rate of BZD administrations by emergency medical services [85].

Tables 2 provide a detailed overview of the studies discussed in this section.

2.3 Diazepam

DZP is a BZD with a relatively long half-life compared to other drugs in this class. DZP is approved by the FDA and EMA for the treatment of anxiety, acute alcohol withdrawal, skeletal muscle spasms and convulsive disorders, such as SE. In addition, it is commonly used off-label for numerous other conditions including insomnia, restless legs syndrome, and pre-/post-operative sedation [86]. DZP is available as an oral tablet, oral solution, as preparations for i.v. or i.m. use and, since 2020, as a ready-made solution with a one-way applicator for i.n. administration.

2.3.1 Pharmacodynamics, Pharmacokinetics and Metabolism

DZP interacts with alcohol and many different classes of drugs, including analgesics, antibiotics, anticonvulsants and antidepressants. In addition, oral contraceptives can inhibit the biotransformation of DZP, thereby increasing its effects and possibly increasing the incidence of break-through bleeding [87]. However, DZP should be avoided in pregnant

△ Adis
Table 2 Summary of studies on the use of midazolam for status epilepticus

| Delivery route | Study design | n    | Age (years) | SE types | Dosage (mg) | Seizure control (%) | TEAE rate (%) | Frequent TEAE (%) | Ref. |
|---------------|--------------|------|-------------|----------|-------------|---------------------|---------------|------------------|------|
| Intravenous   | PS, OLS      | 19   | 16–87       | RSE      | 0.2 bolus then, 1 μg/kg/min | 94.7           | 21              | Pharyngeal hypersecretion | [69] |
|               | ReS          | 20   | 17–81       | RSE      | 2–12 bolus then 0.05–0.8 μg/kg/h | 67             | -               | -                | [70] |
| Intramuscular | RCT, DB, MC  | 102  | 0–102       | SE       | 10          | 73.4               | -             | Endotracheal intubation (14), hypotension (3) | [48] |
|               | MDZ vs. i.v. LZP | Secondary Analysis | 120   | 0–17       | SE       | 5–10          | 68.3           | Inferior to LZP | ICU care | [52] |
|               | MDZ vs. rectal DZP | RCT | 100   | 0–16       | SE       | 0.3 bolus    | 96             | 0                | -                | [74] |
|               | MDZ + p.o. PHT vs. p.o. CBZ | PS, OLS | 38   | –          | SE       | 15            | 84             | Drowsiness | -                | [73] |
| Buccal        | OLS, SC      | 19   | 0–15        | S, SE    | 0.3 bolus   | 100 (AS), 50 (SE) | -             | -                | -                | [76] |
|               | OLS, SC      | 10   | 23–47       | HV       | 10          | -             | -             | -                | -                | [13] |
|               | PS           | 22   | 25–68       | SE       | 15.5        | 83.3           | 21             | Tiredness ataxia | -                | [77] |
|               | RCT, OLS, SC | 18   | 5–19        | S        | 10          | 75             | -             | Mild decrease in blood pressure | -                | [75] |
| Intranasal    | OLS          | 175  | 12–62       | RS       | 5–10        | 55             | 40–57         | Nasal discomfort somnolence headache | [80] |
|               | OLS          | 292  | 12–65       | RS       | 5           | 54             | 2)            | Nasal discomfort somnolence | -                | [197] |
|               | OLS, CO, SC  | 6    | 27–47       | HV       | 5           | -             | -             | Temporary nasal irritation | -                | [58] |
|               | ReS, SC      | 50   | 38.6 (SD 14.0) | S, RS   | 3 MDZ or 1–2 LZP | No difference | 30.4 MDZ | Somnolence | -                | [84] |
|               | RCT          | 70   | 0–15        | S        | 0.2 bolus   | Inferior to DZP | 0             | -                | Respiratory insufficiency (6) intubation (2) | [81] |
|               | PS, RCT, SC  | 358  | < 18        | S        | 0.2 bolus   | Not inferior to DZP | -             | -                | -                | [14] |
|               | PS, OLS      | 24   | 25–69       | RS, SE, RSE | 10         | 82             | Drowsiness (68), local irritation (29) | -                | [83] |

RCT randomized controlled trial, OLS open-label study, SC single-centre, MC multicentre, DB double-blind, PS prospective study, ReS retrospective study, CO cross-over, HV healthy volunteer, S seizure, RS repetitive seizure, SE status epilepticus, RSE refractory status epilepticus, TEAE treatment-emergent adverse event, i.v. intravenous, i.n. intranasal, i.m. intramuscular, p.o. oral, s.l. sublingual, MDZ midazolam, LZP lorazepam, CZP clonazepam, DZP diazepam, PHT phenytoin, CBZ carbamazepine

*Milligram per kilogram body weight (mg/kg BW)
women as there is evidence for an increased risk of harmful effects on the human fetus or neonate without causing malformations [88].

With a $V_d$ of 0.95 to 2.01 L/kg, DZP is a widely distributed compound showing a bioavailability of 93–100% after p.o. administration, 90% after r.s. administration, and 97% after i.n. administration [89–92]. Peak plasma levels are reached after 30–90 min following p.o. administration, 30–60 min after i.m. injection, 10–45 min after r.s. administration, 45 min after i.n., administration, and < 5 min after i.v. delivery. With chronic dosing, steady-state levels are reached after 5–14 days [89–92]. The half-life of DZP is 24–48 h due to an extended redistribution into the muscle and fat tissue after initial adsorption [90]. However, the half-life and free fraction of DZP increases in aged populations due to reduced carrier albumin serum levels and a high plasma protein binding of > 98% [93, 94]. The metabolism of DZP is mediated by hepatic CYP450 enzymes and glucuronidation for the renal elimination of several metabolites; however, marginal amounts of unmetabolized DZP can be found in the urine [95].

### 2.3.2 Available Formulations

DZP is available as a tablet (2 mg, 5 mg and 10 mg tablets) or a concentrate (10 mg/ml) for oral use, as a rectal suppository (10 mg/suppository), as rectal enema (5 mg/vial, 10 mg/vial; also as a rectal gel in an administration device), and as solution for i.v. injection (5 mg/ml, available as a clear water solution and as a lipid emulsion). In the USA, an FDA-approved ready-to-use DZP nasal spray has been available since 2020 under the trade name VOLTOCO® (5 mg/0.1 ml, 7.5 mg/0.1 ml and 10 mg/0.1 ml) for seizure clusters or repetitive seizures in patients aged 6 years or older [89].

### 2.3.3 Clinical Efficacy

For i.n. use, there are four phase I studies in healthy volunteers showing a feasible pharmacokinetic profile for DZP [96–99]. Another study in healthy volunteers revealed that i.m. administration of DZP resulted in a more rapid and less variable drug absorption compared to r.s. delivery [100]. Overall, three phase II studies for DZP were identified that compared rectal gel to i.n. [92] or i.m. administration using an auto-injector [101, 102] for the treatment of repetitive seizures.

For phase III studies, two double-blinded, multicentre, randomized controlled trials and one single-centre open-label trial were found, which revealed significant increases in seizure-free intervals in patients with seizure clusters using a DZP auto-injector. The seizure termination rate in these studies was approximately 78% [103, 104]. The efficacy of p.o., i.v. or r.s. DZP at doses of 0.2–0.5 mg/kg, or up to 20 mg, for the termination of seizures, seizure clusters or SE in general has been extensively demonstrated [22, 28, 29, 105–115]. Subsequently, several studies have compared the efficacy of DZP and valproate (VPA) for terminating SE and showed a response rate of 56–85% for DZP and 50–80% for VPA [116, 117]. Additional studies comparing the i.v. use of DZP to LZP or MDZ revealed a SE cessation rate of 72–100% [46, 50, 51, 118, 119]. However, in some studies, multiple doses were required to finally gain seizure control [120]. Other studies comparing the combination of i.v. DZP plus PHT with i.v. LZP or PB treatment showed a cessation of seizures or SE in 56–100% of cases for DZP [40, 121, 122]. Further studies have compared the efficacy of DZP with i.m. MDZ, revealing a seizure control rate of 88–91% for i.m. and i.v. DZP, respectively [72, 123, 124], and a 94% rate for the r.s. delivery of DZP [74]. Comparative studies examining the differences between i.n. or buccal/sublingual MDZ or LZP and DZP showed a cessation rate of 65–93% for i.v. DZP [15, 125–130], and 45–100% for the r.s. administration of DZP [12, 75, 77, 83, 131–138]. In addition, several reports have revealed no differences in efficacy between i.n. MDZ or LZP and DZP [14, 139]. For a detailed overview of the mentioned studies please refer to Table 3.

With regard to the safety and tolerability of DZP, frequent substance-specific treatment-emergent adverse events (TEAEs) have been identified, including somnolence, sedation, drowsiness, vomiting, hyperactivity, tiredness, hypotension and ataxia [77, 83, 107, 113, 120, 124, 135]. Several severe TEAEs have also been reported, mostly due to respiratory depression that, in some cases, required mechanical ventilation [50, 72, 117, 118, 121]. In addition, different TEAEs have been reported that are specific to the individual routes of administration. For example, injection site pain for i.m. [103, 104], thrombophlebitis for i.v. [123], and nasal discomfort for i.n. administration [92, 101, 102].

### 2.4 Clonazepam

CZP has been used for over 40 years to treat seizures, paediatric and adult SE, chronic epilepsy (including severe childhood epilepsy, such as Lennox-Gastaut syndrome, absence or myoclonic seizures), and—in the USA—panic disorders. Evidence supporting the efficacy of CZP for SE is still scarce, mainly consisting of uncontrolled case series. Therefore, even if widely used in Latin America and in many European countries, CZP is still not recommended by the latest European or American SE guidelines [38, 140]. Various formulations and routes of delivery for CZP exist. However, their availability varies among countries. For example, i.v. formulations are not available in the USA, while disintegrating tablets are not accessible in Europe.

Most of the existing data regarding CZP efficacy for the treatment of SE or seizure clusters are based on i.v.
### Table 3 Summary of studies on the use of diazepam for status epilepticus

| Delivery route | Study design | N  | Age (years) | SE types | Dosage (mg) | Seizure control (%) | TEAE rate (%) | Frequent TEAE (%) | References |
|---------------|--------------|----|-------------|----------|-------------|---------------------|---------------|-------------------|------------|
| Intravenous   |              |    |             |          |             |                     |               |                   |            |
| DZP           | SC           | 15 | 16–73       | RS, SE   | 5–40        | 82                  | –             | –                 | [114]      |
| DZP           | RCT, MC      | 21 | 0–2         | RS       | –           | 87                  | –             | Respiratory arrest| [111]      |
| DZP infusion  | ReS, SC      | 62 | 1–12        | RSE      | 0.017 mg/kg/min | 86          | –             | Hypotension, respiratory depression| [113]      |
| DZP vs. i.v. VPA | RCT, SC     | 20 | 0–12        | RSE      | 10          | 85                  | –             | Respiratory depression| [117]      |
| DZP vs. i.v. VPA | PS         | 66 | 41           | SE       | 2 × 0.2b in 10 min | 56          | –             | –                 | [116]      |
| DZP vs. i.v. LZP | RCT, DB, SC | 78 | –           | S        | 5           | 76                  | –             | Respiratory depression| [46]       |
| DZP vs. i.v. LZP | RCT, MC     | 273| 0–17        | SE        | –           | Not superior        | –             | Respiratory depression| [139]      |
| DZP vs. i.v. LZP vs. i.v. placebo | RCT, DB, SC | 205| ≥ 18        | SE        | 5           | Superior to placebo | –             | Respiratory complications, circulatory complications| [22]       |
| DZP vs. i.v. LZP and rectal DZP vs. rectal LZP | RCT, SC | 53 | 3.3–6.6 | SE | 0.3–0.4b | 85 (i.v.) 37 (rectal) | 15 | Respiratory depression | [51]       |
| DZP + PHT vs. i.v. LZP vs. i.v. PH | RCT, DB, MC | 570 | 58.6 | SE | 0.15b | 56 | – | Hypoventilation, cardiac arrhythmia | [47]       |
| DZP vs. i.v. LZP | RCT, SC | 88 | 1–12 | SE | 0.2b (+ 18b PHT) | 100 | – | Respiratory depression | [121]      |
| DZP vs. i.v. MDZ | RCT, SC | 19 | 2–12 | RSE | 0.5a | 90 | – | Respiratory depression | [118]      |
| DZP vs. i.v. MDZ | RCT           | 120 | Children | S | 0.3–0.5b | 100 | – | – | [119]      |
| DZP vs. i.v. MDZ vs. i.v. LZP | RCT, SC | 120 | 0–14 | S | 0.3b | 73 | – | Somnolence, sedation | [198]      |
| DZP + PHT vs. PB + PHT | RCT, SC | 36 | 43.8 | SE | 2/min | Inferior to PB | – | Respiratory failure | [122]      |
| DZP vs. i.n. MDZ | RCT, SB, SC | 35 | 0–15 | S | 0.2b | Superior to MDZ | – | – | [81]       |
| DZP vs. i.n. MDZ | RCT, SC | 60 | 0–15 | S | 0.3b | Inferior to MDZ | – | – | [127]      |
| DZP vs. i.n. MDZ | RCT, SC | 50 | 1–12 | S | 0.3b | 65 | – | – | [15]       |
| DZP vs. i.n. MDZ | RCT, SC | 125 | – | S | 0.3b | Inferior to MDZ | – | – | [130]      |
| DZP vs. i.m. MDZ | RCT, SC | 115 | 0–12 | S | 0.2b | – | 11 | Thrombophlebitis | [123]      |
| DZP vs. i.m. MDZ | RCT, SC | 32 | 0–14 | S | 0.5b | 88 | – | Vomiting, hyperactivity | [124]      |
| DZP vs. i.m. MDZ | RCT, SC | 11 | 0–10 | SE | 0.3b | 91 | 9 | Respiratory depression | [72]       |
Table 3 (continued)

| Delivery route                  | Study design     | N   | Age (years) | SE types | Dosage (mg) | Seizure control (%) | TEAE rate (%) | Frequent TEAE (%) | References  |
|---------------------------------|------------------|-----|-------------|----------|-------------|--------------------|---------------|-------------------|-------------|
| DZP vs. buccal MDZ              | RCT, SC          | 120 | 0–12        | S        | 0.3b       | 93.3               | –             | –                 | [128]       |
| DZP vs. buccal MDZ              | RCT, SC          | 92  | 0–14        | S        | 0.3b       | 70                 | 42            | Respiratory failure | [129]       |
| Intramuscular                   |                  |     |             |          |             |                    |               |                   |             |
| DZP                             | RCT, DB, MC      | 234 | ≥ 2         | RS       | 5, 10, 15, 20a | Reduction of time to next seizure | 42            |                   | [103]       |
| DZP                             | RCT, MC          | 234 | 2–83        | RS       | 5, 10, 15a  | 78                 | 75            |                   | [104]       |
| DZP vs. i.m. rectal gel         | SC, OLS          | 24  | 18–55       | HV       | 10         | i.m. superior to rectal | –             | Pain, discomfort, drowsiness | [100]       |
| DZP vs. DZP rectal gel          | RCT, DB, SC, CO  | 48  | 18–40       | RS       | 5, 10, 15a  | –                  | 22            | Injection site discomfort | [101]       |
| Rectal (gel or solution)        |                  |     |             |          |             |                    |               |                   |             |
| DZP                             | ReS, SC          | 50  | 34.7c       | RS       | 0.2b       | 90                 | –             | Somnolence        | [107]       |
| DZP                             | SC               | 39  | 16–65       | RS       | 20, 30      | 29–72              | –             | Drowsiness        | [108]       |
| DZP                             | SC               | 17  | –           | RS       | 0.5b       | 66                 | –             | Respiratory difficulties, dizziness | [115]       |
| DZP                             | OLS              | 149 | 2–76        | RS       | 0.2–0.5b   | 77                 | –             | Sedation         | [109]       |
| DZP vs. placebo                 | RCT, DB, MC      | 96  | ≥ 18        | RS       | 0.2b       | –                  | –             | –                 | [105]       |
| DZP vs. placebo                 | RCT, DB          | 125 | 2–60        | RS       | 0.2–0.5b   | Superior to placebo | –             | –                 | [28]        |
| DZP (rectal or p.o.) vs. placebo| RCT, DB, SC      | 40  | 18–60       | RS       | 20         | Superior to placebo | –             | –                 | [110]       |
| DZP vs. placebo                 | RCT, DB, MC      | 158 | > 2         | RS       | 0.2–0.5b   | 55                 | –             | Somnolence        | [29]        |
| DZP vs. placebo                 | PS, DB           | 133 | 2–17        | RS       | 5          | Superior to placebo | –             | Somnolence        | [112]       |
| DZP vs. i.m. MDZ                | RCT, SC          | 100 | 0–16        | SE       | 0.5b       | 94                 | –             | –                 | [74]        |
| DZP vs. buccal MDZ              | RCT, MC          | 110 | 0–15        | S        | 2.5–10     | 45                 | 6             | Respiratory depression | [12]        |
| DZP vs. buccal MDZ              | RCT, SB, SC      | 165 | 0–12        | S        | 2.5–10     | 57                 | –             | Respiratory depression | [131]       |
| DZP vs. buccal MDZ              | RCT, SC          | 39  | 5–22        | S        | 10         | 59                 | –             | –                 | [75]        |
| DZP vs. buccal MDZ              | RCT, SC          | 98  | 0–12        | S        | 0.5b       | 82                 | –             | –                 | [132]       |
| DZP vs. buccal MDZ              | RCT, SC          | 43  | 0–12        | S        | 0.3–0.5b   | 85                 | –             | –                 | [133]       |
### Table 3 (continued)

| Delivery route | Study design | N   | Age (years) | SE types | Dosage (mg) | Seizure control (%) | TEAE rate (%) | Frequent TEAE (%) | References |
|----------------|--------------|-----|-------------|----------|-------------|---------------------|--------------|-------------------|------------|
| DZP vs. buccal MDZ | RCT, SC       | 22  | 25–82       | S        | 5           | 83                  | –             | Tiredness, ataxia | [77]       |
| DZP vs. buccal MDZ | RCT, SC       | 34  | 0–18        | S        | 0.5<sup>b</sup> | 100               | –            | –                 | [136]      |
| DZP vs. sublingual LZP | RCT, MC      | 436 | 0–10        | S        | 0.5<sup>b</sup> | 79                 | –             | –                 | [137]      |
| DZP vs. i.n. MDZ | RCT, SC       | 45  | 0–13        | S        | 0.3<sup>b</sup> | 60                 | –             | –                 | [134]      |
| DZP vs. i.n. MDZ | RCT, SC       | 46  | 0–12        | S        | 0.3<sup>b</sup> | 89                 | –             | Vomiting, drowsiness, hypoxia | [135] |
| DZP vs. i.n. MDZ | PS, SC        | 21  | 25–69       | S        | 10          | 89                 | –             | Drowsiness       | [83]       |
| DZP vs. i.n. MDZ | RCT, SB, MC   | 358 | 3–11        | S        | 0.3–0.5<sup>b</sup> | Not superior | –            | Respiratory failure (1) | [14]       |
| DZP vs. i.n. MDZ | RCT, MC       | 358 | –           | RS       | 0.3–0.5<sup>b</sup> | –              | –             | –                 | [138]      |
| **Intranasal**   |              |     |             |          |             |                    |              |                   |            |
| DZP             | Pilot study   | 24  | 18–45       | HV       | 10          | –                   | –             | –                 | [96]       |
| DZP             | Pilot study   | 8   | 28.3<sup>c</sup> | HV       | 5, 10       | –                   | –             | –                 | [98]       |
| DZP             | MC            | 78  | 18–65       | S        | 0.2<sup>b</sup> | –                   | –             | Nasopharyngeal signs | [92]       |
| DZP vs. i.v. MZD | Pilot study   | 4   | 20–24       | HV       | 5           | –                   | –             | –                 | [99]       |
| DZP vs. rectal gel | OLS, CO      | 24  | 18–50       | RS       | 5, 20<sup>a</sup> | –               | 32–48         | Nasal redness, nasal discomfort | [102]       |
| DZP vs. i.v. DZP | Pilot study   | 9   | 20–30       | HV       | 20 (i.n.) 2 (i.v.) | –               | –             | –                 | [97]       |

*RCT* randomized controlled trial, *OLS* open-label study, *SC* single-centre, *MC* multicentre, *DB* double-blind, *PS* prospective study, *RS* retrospective study, *CO* cross-over, *HV* healthy volunteer, *S* seizure, *RS* repetitive seizure, *SE* status epilepticus, *RSE* refractory status epilepticus, *TEAE* treatment-emergent adverse event, *i.v.* intravenous, *i.n.* intranasal, *i.m.* intramuscular, *p.o.* oral, *MDZ* midazolam, *LZP* lorazepam, *DZP* diazepam, *VPA* valproate, *PHT* phenytoin, *PB* phenobarbital

<sup>a</sup> Absolute  
<sup>b</sup> Milligram per kilogram body weight (mg/kg BW)  
<sup>c</sup> Average
administration studies [53, 141–147]. Anecdotal evidence exists regarding the wafer formulation (orally disintegrating tablets) [148], and only phase I and II trials have been conducted for i.n. [149], r.s. [150], i.m. [151], oral droplets [152] or subcutaneous [153] formulations.

2.4.1 Pharmacodynamics, Pharmacokinetics and Metabolism

CZP is more lipophilic than LZP, but less so than DZP, with consequently less redistribution compared to the latter drug. Its protein binding is 86%, which is somewhat lower than for other BZDs. After i.v. administration, CZP reaches the brain within 1 min, and its distribution follows a two-compartment model with a half-life from 0.7 to 3.4 h and a $V_d$ from 1.5 to 4.4 L/kg [40]. After p.o. administration, CZP is completely absorbed with an absolute bioavailability of ~90% ($T_{\text{max}}$ is achieved within 1–4 h) [154].

In a preclinical study, i.n. CZP administration using nanocarriers was demonstrated to be safe and effective [149], and oral droplet administration (with CZP dissolved into droplets of propylene glycol) has been shown to achieve therapeutic levels within 10–15 min [152].

Rectal administration (11 healthy children with previous febrile convolution, six aged 1.4–4.7 years at a dose of 0.05 mg/kg, and 5 aged 1.4–4.1 years at a dose of 0.1 mg/kg) showed plasma concentrations indicating a rapid absorption ($T_{\text{max}}$ 10 min–2 h, mean 30 min) [150]. One open-label study investigating the pharmacokinetics of i.v., i.m. and p.o. CZP (2 mg) reported a slower absorption rate after i.m. administration compared to p.o. administration ($T_{\text{max}}$ 3.1 h vs. 1.7 h) [151].

Subcutaneous injection of CZP (microspheres) demonstrated complete absorption with a slow-release pharmacokinetic profile [153]. CZP has a long half-life of 30–40 h and undergoes extensive metabolism, primarily by CYP3A4, with no formation of active metabolites. Due to its extensive CYP450 metabolism, several drug interactions exist. For example, CYP450 inducers, such as PHT, CBZ, lamotrigine (LTG) or PB, can cause a 38% decrease in CZP plasma levels. Similarly, CYP inhibitors, such as antifungal agents, may impair CZP metabolism [154, 155]. CZP can be kept at ambient temperature and can be administered as a rapid i.v. bolus (0.015 mg/kg, over ≤ 30 s).

2.4.2 Available Formulations

CZP is available as a tablet (0.5 mg and 2 mg tablets), orally disintegrating tablet and concentrate (2.5 mg/ml) for oral use and as solution for i.v. injection (1 mg/ml).

2.4.3 Clinical Efficacy

Since the first clinical publication by Gastaut in 1971 [142], few clinical trials have been conducted to evaluate the efficacy of CZP for SE. In addition to the trials described below, eight uncontrolled case series from the 1970s (a total of 385 patients) reported CZP to be effective in approximately 80–90% of patients [144]. In the initial publication, Gastaut and colleagues reported SE termination, without unfavorable side effects, in 38/39 SE episodes treated with i.v. CZP (1–8 mg) [142]. In children, an early study (17 children, age 2 weeks to 15 years) reported SE cessation after i.v. CZP (0.25–0.75 mg) in all cases without significant side effects [141].

More recently, two retrospective studies suggested that i.v. CZP may not be inferior—and may even be superior—to other BZDs [53, 145]. A retrospective multicentre study including 177 adult patients reported the prescription of CZP as a first-line treatment in 72 (41%) SE patients, with 82 (46%) and 23 (13%) using LZP and MDZ, respectively. Interestingly, only 85% of the patients received BZDs as a first-line treatment and 59% were prescribed an insufficient dosage [53]. A single-centre retrospective assessment of 167 SE episodes described i.v. CZP as the most effective treatment (50% response rate) for terminating GCSE compared to i.v. DZP (18%), i.v. LZP (29%) or i.m. MDZ (12%) [145]. Even if not designed to evaluate CZP efficacy, a randomized double-blind trial (SAMUKeppra) evaluating i.v. levetiracetam (LEV; 2.5 g) plus i.v. CZP (1 mg) versus placebo plus i.v. CZP in outpatient GCSE treatment offered good insights regarding CZP efficacy [143]. No advantage was found with the addition of LEV over CZP alone. Convulsions stopped after 15 min in 84% (57/68) of patients receiving CZP alone [143]. Regarding non-i.v. formulations, a retrospective study investigating the efficacy of CZP wafers for the acute treatment of prolonged seizures in children and young adults (2–25 years) reported SE termination, without unfavorable side effects, in 38/39 SE episodes treated with i.v. LZP and MDZ, respectively.

Interestingly, only 85% of the patients received BZDs as a first-line treatment and 59% were prescribed an insufficient dosage [53]. A single-centre retrospective assessment of 167 SE episodes described i.v. CZP as the most effective treatment (50% response rate) for terminating GCSE compared to i.v. DZP (18%), i.v. LZP (29%) or i.m. MDZ (12%) [145]. Even if not designed to evaluate CZP efficacy, a randomized double-blind trial (SAMUKeppra) evaluating i.v. levetiracetam (LEV; 2.5 g) plus i.v. CZP (1 mg) versus placebo plus i.v. CZP in outpatient GCSE treatment offered good insights regarding CZP efficacy [143]. No advantage was found with the addition of LEV over CZP alone. Convulsions stopped after 15 min in 84% (57/68) of patients receiving CZP alone [143]. Regarding non-i.v. formulations, a retrospective study investigating the efficacy of CZP wafers for the acute treatment of prolonged seizures in children and young adults (2–25 years) reported SE termination, without unfavorable side effects, in 38/39 SE episodes treated with i.v. LZP and MDZ, respectively.

Seizure termination was reported within 1 min, perhaps partially corresponding to a spontaneous termination.

In conclusion, although class I evidence is currently lacking, i.v. CZP, which is already widely used, constitutes a good option for first-line SE treatment. Regarding alternative routes of administration, p.o. administration (CZP wafers) and i.m. administration is not recommended due to its slower absorption rate, and—despite promising phase I–II studies—in.n. and r.s. formulations are not yet available.

Tables 4 provide a detailed overview of the studies discussed in this section.
### Table 4: Summary of studies on the use of clonazepam for status epilepticus

| Delivery route | Study design | n  | Age (years) | SE types | Dosage (mg) | Seizure control (%) | TEAE rate (%) | Frequent TEAE (%) | Ref. |
|---------------|--------------|----|-------------|----------|-------------|---------------------|---------------|-------------------|------|
| **Per os**    |              |    |             |          |             |                     |               |                   |      |
| CZP           | ReS, SC      | 56 | 2–25        | RS, SE   | 0.25, 0.5, 1 or 2 | 68                  | –             | –                 | [148]|
| **Intravenous** |              |    |             |          |             |                     |               |                   |      |
| CZP           | –            | 16 | –           | SE       | 1           | 88                  | –             | –                 | [199, 200]|
| CZP           | –            | 17 | –           | SE       | 1–6         | 82                  | –             | –                 | [201]|
| CZP           | –            | 194| –           | SE       | 0.5–10      | 81 (19 multiple doses) | – | Respiratory depression, somnolence | [202]|
| CZP vs. PS, OLS, SC | 8 – | SE | 2           | 100 | – | Drowsiness, ataxia | [203]|
| CZP           | PS, OLS, SC  | 65 | –           | SE       | 1–4         | 83                  | –             | Respiratory depression, somnolence | [204]|
| CZP           | PS, OLS, SC  | 40 | < 18        | SE       | 0.5–2       | 75                  | –             | –                 | [205]|
| CZP           | –            | 13 | 0.15–15     | SE       | 0.4–3       | 77                  | –             | –                 | [206]|
| CZP           | –            | 32 | –           | SE       | 2           | 84                  | –             | –                 | [207]|
| CZP vs. ReS, OLS, SC | 17 0–15 | SE | 0.25–0.75   | 100 | – | Respiratory depression, drowsiness | [141]|
| CZP           | OLS          | 24 | –           | SE, RS   | 1–2         | 100 (focal aware), 66 (focal unaware) 50 (GTC) | 42 | Respiratory depression, drowsiness | [146]|
| CZP (bolus vs. perfusion) | ReS, OLS, SC | 37 | –           | SE       | 1–8         | 97                  | –             | –                 | [142]|
| CZP vs. i.v. LZP vs. i.v. LZP + CZP | OLS | 61 | ≥ 18        | SE       | 1           | 76                  | –             | Drowsiness, psychomotor agitation | [147]|
| CZP vs. i.v. DZP vs. i.v. LCM vs. i.v. LEV vs. i.v. LZP vs. i.v. MDZ vs. i.v. PHT vs. i.v. VPA | ReS, SC | 167 | 63.1 (SD 17.4) | S, SE, RSE | 1.2 (SD 1)–5.5 (SD 5.3) | 50 | – | Respiratory, drowsiness | [145]|
| CZP           | PS, OLS, MC  | 177| ≥ 16        | SE, RS   | 0.015\a | 56.96 (endpoint: not RSE) | – | – | [53]|
| CZP vs. i.v. LZP vs. i.v. MDZ | PS, OLS, MC | 177 | ≥ 16 | SE, RS | 0.015\a | 56.96 (endpoint: not RSE) | – | – | [53]|
| CZP + placebo vs. i.v. CZP + LEV | RCT, DB | 205 | S, RS | 1 | 84 | 19 | Respiratory failure, cardiac failure | [143]|

*RCT* randomized controlled trial, *OLS* open-label study, *SC* single-centre, *MC* multicentre, *DB* double-blind, *PS* prospective study, *ReS* retrospective study, *S* seizure, *RS* repetitive seizure, *SE* status epilepticus, *RSE* refractory status epilepticus, *GTC* generalized tonic clonic seizure, *TEAE* treatment-emergent adverse event, *i.v.* intravenous, *p.o.* oral, *MDZ* midazolam, *LZP* lorazepam, *CZP* clonazepam, *VPA* valproate, *PHT* phenytoin, *LCM* lacosamide, *LEV* levetiracetam

*\a Milligram per kilogram body weight (mg/kg BW)*
2.5 General Considerations

We would like to point out that, although the previously discussed established pharmacokinetic and pharmacodynamic measures provide a good overview of how a drug acts, additional factors might contribute to complex drug behaviors. For instance, time of maximum concentration in plasma after IV administration does not necessarily correspond to the time of maximum pharmacologic effect, for example due to the delay in diffusion across the blood-brain barrier [156–158]. Furthermore, the half-life of a drug might not necessarily correspond to the duration of action (as mentioned above), which, for example, also depends on the size of the dose and the extent of peripheral tissue distribution during the initial distribution phase.

2.6 Group-Specific Side Effects

All benzodiazepines can—due to their action as a GABA_A-receptor agonists—cause amnesia, sedation, respiratory depression and coma. Therefore, after administration, monitoring of the patient’s clinical status, especially vigilance breathing, and protective reflexes is mandatory. In case of a severe respiratory depression, protective intubation usually involving muscle relaxants can be necessary, which in turn hinders further evaluations of the patient’s clinical status, neurological assessment and seizure detection without EEG. Furthermore, consequent admission to the intensive care unit might increase the risk of ventilation-associated pneumonia, which in turn can promote refractory SE and lead to poorer outcome [159–161]. Though, it should be mentioned that SE per se can also cause severe respiratory depression.

As side effects depend on dose and time of action, choice of an adequate initial dose and of a short-acting drug are important factors (e.g., MDZ i.v. or the newer formulations). The benzodiazepine effect can further be counteracted by the BZD antagonist flumazenil.

Of the discussed benzodiazepines, all but LZP are mainly metabolized via CYP450 enzymes and glucuronidation for the renal elimination of metabolites. LZP in turn is metabolized by hepatic one-step, non-oxidative conjugation after which the non-active metabolite is predominantly excreted renally. This might make LZP a preferential choice in patients with liver disease. Dose adjustments should be made according to product labels.

3 Novel Administration Routes and Other Benzodiazepines

New routes of drug administration, such as the intrapulmonary route, are currently being investigated for the treatment of epilepsy and other disorders [162, 163]. Due to a large surface area, and high permeability and blood flow in the lung, rapid systemic drug effects are possible with inhalation therapies [164]. Therefore, intrapulmonary administration for the treatment of SE seems promising. In 1994, Xi et al. treated 120 patients with seizures in a single-blind trial with inhalable DZP and showed a significant effect on seizure control [165]. Dhir and colleagues also showed that MDZ and a propofol prodrug are highly effective antiseizure drugs when administered intrapulmonarily in a preclinical model [166, 167]. Currently, intrapulmonary administration of alprazolam delivered via the Staccato delivery system is being developed as a rapid epileptic seizure termination therapy. This drug delivery system vaporizes the drug through a heating package that is activated by breathing through the system. The drug vapor condenses into aerosol particles and is delivered into the lungs by normal breathing.

Alprazolam is a 1,4-benzodiazepine and also an allosteric modulator of GABA_A-receptors. This drug was approved by the FDA for the treatment of anxiety and panic disorders in 1981 and is available for p.o. administration [168]. Alprazolam does not have an indication for seizure therapy at present, but preclinical studies suggest that it does have a potent antiseizure effect [164]. After p.o. administration, peak concentration in the plasma is reached in 1–2 h and is proportionate to the dose. Single doses usually range from 0.5–3 mg and result in peak levels of 8–37 ng/ml. Alprazolam has an intermediate onset of action (function of rate of absorption) compared to other BZDs and mean plasma elimination half-life of ~6–15 h [169, 170]. In a phase I study, 1 mg of inhaled alprazolam reached a peak concentration of 48 ng/ml in smokers and 26.72 ng/ml in non-smokers after 1.8 min [171]. In vitro, alprazolam is mostly bound to serum albumin (80%). It is mainly metabolized by CYP3A4, which means that pharmacological interactions must be considered. The two main metabolites of alprazolam are 4-hydroxyalprazolam and α-hydroxyalprazolam, both of which have low plasma concentrations in comparison to alprazolam and do not contribute to the pharmacological effects of this drug.
Alprazolam and its metabolites are excreted primarily in the urine [171]. In a phase IIa study, five patients with a diagnosis of photoparoxysmal response on EEG received alprazolam intrapulmonarily via the Staccato system in 0.5–2 mg doses after intermittent photic stimulation [164]. The number of photic stimulation frequencies that produced a photoepileptiform response was measured after inhalation. Staccato alprazolam reduced the number of photic stimulation frequencies at 2 min compared to placebo, and the effect stopped after 4 h for the 0.5 mg dose and after 6 h for the 1 and 2 mg doses. Alprazolam plasma concentrations were dose related and reached 31.5 ± 3.14 ng/ml within 2 mins after the inhalation of 2 mg [164].

Potential limitations include the patient’s compliance, insufficient spontaneous breathing during seizures, or reduced transpulmonary diffusion capacity. The results of a phase IIb randomized, double-blind, inpatient study and phase III studies exploring the efficacy and safety of Staccato alprazolam for the acute termination of a predictable seizure pattern are currently pending.

4 Special Therapeutic Aspects for Infants and Children

4.1 Particular Features of the Pharmacokinetics of Benzodiazepines (BZDs) in Children

As with many other drugs, the pharmacokinetics of BDZs vary with age. This is mainly due to the maturation of the hepatic microsomal oxidizing system over the 6 months after birth. Consequently, the pharmacokinetics of hepatic metabolized pharmaceuticals in children less than 6 months of age are significantly different from adults. Cytochrome P450-catalyzed metabolism tends to be low at birth but exceeds adult values by 2–3 years of age. Thereafter, CYP-catalyzed metabolism decreases again, reaching adult levels
4.2 Rescue Medications in Paediatric Epilepsy Patients

Rescue medications for lay use are frequently prescribed for paediatric epilepsy patients. The availability of such preparations differs between the USA and the EU. Oromucosal MDZ (Buccolam®) is a BZD approved by the EMA—but not by the FDA—for the treatment of paediatric patients aged 3 months to < 18 years with prolonged, convulsive seizures [177]. The ready-to-use, prefilled oral syringes containing a MDZ solution (in a concentration of 5 mg/ml with different volumes to provide an age-appropriate dose) are administered in fixed doses depending on the patient’s age. The recommended doses are 2.5 mg (in patients aged 3 months to < 1 year), 5 mg (in patients aged 1 year to < 5 years), 7.5 mg (in patients aged 5 years to < 10 years), and 10 mg (in patients aged 10 years to < 18 years) [178]. Oromucosal MDZ (0.2–0.5 mg/kg or 10 mg) is at least as effective as r.s. DZP (~0.5 mg/kg or 10 mg), and as effective as i.v. DZP (0.3 mg/kg) with regard to response rate (cessation of seizures) in paediatric patients in randomized, controlled trials [12, 75]. DZP rectal gel is approved by the EMA for epilepsy patients weighing a minimum of 10 kg (a patient age of approximately 1 year), and FDA approval exists for the treatment of occasional episodes of increased seizures that are different from a patient’s usual seizure pattern in patients with epilepsy that are 2 years of age and older [179]. The recommended dose for DZP rectal gel is 0.2–0.5 mg/kg depending on age. The ready-for-use rectal delivery system is provided in unit doses of 2.5, 5, 7.5, 10, 12.5, 15, 17.5 and 20 mg DZP, and the prescribed dose is obtained by rounding upward to the next available dose. DZP nasal spray (VOLTOCO®, FDA approved for epilepsy patients aged 6 years and older) and MDZ nasal spray (Nayzilam®, FDA approved for epilepsy patients aged 12 years and older) are not yet approved in the EU (Fig. 1).

5 Conclusion: Comparing Different BZDs and Delivery Routes for Status Epilepticus

Over the last several decades, different BZDs have been established as first-line therapies for SE, each of which has its own pharmacological characteristics with advantages and disadvantages [180]. Here, the comparably long half-life of DZP especially stands out [181]. As it has been shown that interrupting SE as soon as possible reduces the chance of developing RSE and improves outcomes, ensuring rapid treatment in acute care is at least as important, if not more important, than the BZD choice [182]. Fortunately, several delivery routes for BZDs have now been established, which are suitable for both lay users and medical staff [9]. To provide an overview of the available treatment options.
Table 5  Comparison and dosing of frequently used benzodiazepines for the treatment of status epilepticus

| Drug       | Pharmacokinetics | Dosing and delivery route specific aspects |
|------------|------------------|------------------------------------------|
|            | \( V_{distribution} \) (l/kg) | PB (%) | Half-life \(^a\) (h) | Clearance (ml/min/kg) | Delivery routes | BA (%) | \( T_{max} \) \(^b\) (min) | Initial dose | Initial dose (mg) | Dose repetition (min) | Max. dose (mg) |
| Lorazepam (LZP) | 0.8–1.3         | 90     | 8–20          | 0.7–1.2          | i.v.      | 100    | 10   | 0.1 | 2–4 | 5–10 | 8              |
|            |                  |        |              |                  | i.n.      | 77     | 30   | –   | –   | –    | –               |
|            |                  |        |              |                  | i.m.      | 100    | 80   | –   | –   | –    | –               |
|            |                  |        |              |                  | s.l.      | 94     | 120  | –   | –   | –    | –               |
|            |                  |        |              |                  | i.n.      | 100    | 4.5  | 0.2 | 10  | 5–10 | 10             |
|            |                  |        |              |                  | i.m.      | 78     | 10–15| –   | 5–10| no   | –               |
|            |                  |        |              |                  | buccal    | 91     | 20   | –   | 10  | no   | –               |
|            |                  |        |              |                  | i.v.      | 100    | 4.5  | 0.2 | 10  | 5–10 | 10             |
|            |                  |        |              |                  | i.n.      | 78     | 10–15| –   | 5–10| no   | –               |
|            |                  |        |              |                  | i.m.      | 91     | 20   | –   | 10  | no   | –               |
|            |                  |        |              |                  | buccal    | 75     | 15–90| –   | 5–10| no   | –               |
|            |                  |        |              |                  | i.v.      | 100    | 1    | 0.15–0.2 | 5–10 | 5   | 20             |
|            |                  |        |              |                  | i.n.      | 70–90  | 60–90| –   | –   | –    | –               |
|            |                  |        |              |                  | i.m.      | 100    | 60   | 0.1–0.2 | 5–10 | –   | 30             |
|            |                  |        |              |                  | r.s.      | 80–100 | 30–74| 0.2–0.5 | 10–30| no  | 20             |
| Clonazepam (CZP) | 3               | 86     | 17–55        | 0.42            | i.v.      | 90     | < 10 | 0.015 | 1–2  | 5–10 | 2              |
|            |                  |        |              |                  | i.m.      | 93     | 3.1  | –   | –   | –    | –               |

Modified after [9, 151, 181, 183–185]

\(^a\) Elimination half-life

\(^b\) \( T_{max} \) after administration of a single dose

\( V_{distribution} \): distribution volume

PB: protein binding

BA: bioavailability

\( T_{max} \): time to peak concentration after single dose administration

\( mg/kg BW \): milligram per kilogram body weight

\( h \): hour
Despite their almost complete bioavailability, the $T_{\text{max}}$ to the termination of convulsions was similar \[48\]. In a pharmaco-EEG study, a relevant effect of MDZ after i.n. administration could already be measured after 4 min, which preceded the clinical end of the seizure by ~1 min \[66\]. For lay use, there are also BZD formulations available that can be administered either rectally or buccally. Buccal MDZ can easily be applied into the cheek pouches using prefabricated disposable syringes. With a bioavailability of 75% and a $T_{\text{max}}$ between 15 and 90 min, this delivery route is mainly used in the treatment of seizure series or clusters, but there is a risk of aspiration and the pharmacokinetics can vary greatly depending on mucosal absorption. Therefore, the comprehensive use of buccal MDZ in professional emergency care does not appear to be reasonable. In addition, DZP is available for rectal use as rectioles, which are mainly used in paediatrics. Here, again, a $T_{\text{max}}$ of 30–74 min limits this administration in the professional medical setting, despite almost complete bioavailability. Based on a disproportionately long $T_{\text{max}}$ of approximately 120 min, sublingual LZP is not an adequate therapeutic option for the acute treatment of SE. Other new delivery routes, such as intrapulmonary administration, appear promising but require further studies before clinical use. To ensure further therapeutic management including prevention of potential RSE and for safety reasons, the establishment of a peripheral venous catheter for the repeated administration of BZDs at the earliest possible time seems indispensable.

**Declarations**

**Funding** The authors were supported via the Center for Personalized and Translational Epilepsy Research (CePTER) with a LOEWE grant from the State of Hessen. Open access funding enabled and organized by Projekt DEAL.

**Ethics approval** Not applicable.

**Consent for publication** Not applicable.

**Consent to participate** Not applicable.

**Availability of data and material** Not applicable.

**Code availability** Not applicable.

**Competing Interests** RK, LW, IB, SG, SvB, CM, AL, JHS, KS and LMW declare that they have no conflicts of interest. JPZ reports speakers’ honoraria and travel grants from Eisai and Desitin Arzneimittel. SSB reports personal fees from Eisai, Desitin Pharma, GW Pharmaceuticals companies, LivaNova, UC, and Zogenix. FR reports grants and personal fees from UCB Pharma, Arvelle Therapeutics, and Desitin Arzneimittel, personal fees from Eisai, GW Pharmaceuticals, Novartis, Medtronic, Cerbomed, Sandoz, BayerVital, and Shire, and grants from the European Union, Deutsche Forschungsgemeinschaft, the LOEWE Programm of the state of Hesse, and the Detlev-Wrobel-Fonds for Epilepsy Research. AS reports personal fees and grants from Angelini Pharma/Arvelle Therapeutics, Desitin Arzneimittel, Eisai, GW Pharmaceuticals, Marinus Pharmaceuticals, UCB Pharma, UNEEG medical, and Zogenix. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in this review apart from those disclosed.

**Authors’ contributions** AS developed the idea for this review. AS and RK drafted the concept. All authors performed the literature search and data analysis. AS, RK and LMW drafted the graphical abstract and the final manuscript. All authors contributed substantially to the final manuscript. All authors approved the final manuscript for submission. All authors agree to be accountable for the work.

**Open Access** This article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the
original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/.

References

1. Betjemann JP, Lowenstein DH. Status epilepticus in adults. Lancet Neurol. 2015;14(6):615–24.
2. Roberg LE, Monsson O, Kristensen SB, Dahl SM, Ulvin LB, Heuser K, et al. Prediction of long-term survival after status epilepticus using the ACD score. JAMA Neurol. 2022;79(6):604–13.
3. Schubert-Bast S, Zollner JP, Ansorge S, Hapfelmeier J, Bonthapally V, Eldar-Lissai A, et al. Burden and epidemiology of status epilepticus in infants, children, and adolescents: a population-based study on German health insurance data. Epilepsia. 2019;60(5):911–20.
4. Poukas VS, Pollard JR, Anderson CT. Rescue therapies for seizures. Curr Neurol Neurosci Rep. 2011;11(4):418–22.
5. Humphries LK, Eiland LS. Treatment of acute seizures: is intranasal midazolam a viable option? J Pediatr Pharmacol Ther. 2013;18(2):79–87.
6. Rey E, Treluyer JM, Pons G. Pharmacokinetic optimization of benzodiazepine therapy for acute seizures. Focus on delivery routes. Clin Pharmacokinet. 1999;36(6):409–24.
7. Anderson GD, Saneto RP. Current oral and non-oral routes of antiepileptic drug delivery. Adv Drug Deliv Rev. 2012;64(10):911–8.
8. Kadel J, Bauer S, Hermsen AM, Immisch I, Kay L, Klein KM, et al. Use of emergency medication in adult patients with epilepsy: a multicentre cohort study from Germany. CNS Drugs. 2018;32(8):771–81.
9. Mula M. New non-intravenous routes for benzodiazepines in epilepsy: a clinician perspective. CNS Drugs. 2017;31(1):1–7.
10. Lathers CM, Jim KP, Spivey WH. A comparison of intraosseous and intravenous routes of administration for antiseizure agents. Epilepsia. 1989;30(4):472–9.
11. Kapur J, Macdonald RL. Rapid seizure-induced reduction of benzodiazepine and Zn2+ sensitivity of hippocampal dentate granule cell GABAA receptors. J Neurosci. 1997;17(19):7532–40.
12. McIntyre J, Robertson S, Norris E, Appleton R, Whitehouse WP, Ficker DM, et al. Occurrence of seizure clusters and status epilepticus during inpatient video-EEG monitoring. Neurology. 2003;60(6):975–8.
13. Scott RC, Besag FM, Boyd SG, Berry D, Neville BG. Buccal absorption of midazolam: pharmacokinetics and EEG pharmacodynamics. Epilepsia. 1998;39(3):290–4.
14. Holsti M, Dudley N, Schunk J, Adelgais K, Greenberg R, Olsen C, et al. Intranasal midazolam vs rectal diazepam for the home treatment of acute seizures in pediatric patients with epilepsy. Arch Pediatr Adolesc Med. 2010;164(8):747–53.
15. Thakker A, Shanbag P. A randomized controlled trial of intranasal midazolam versus intravenous-diazepam for acute childhood seizures. J Neurol. 2013;260(2):470–4.
16. Trinka E, Cock H, Hesdorffer D, Rossetti AO, Scheffer IE, Shinnar S, et al. A definition and classification of status epilepticus—report of the ILAE task force on classification of status epilepticus. Epilepsia. 2015;56(10):1515–23.
17. Lowenstein DH, Bleck T, Macdonald RL. It’s time to revise the definition of status epilepticus. Epilepsia. 1999;40(1):120–2.
18. Rosenow F. Status epilepticus im Erwachsenenalter. In: Diener HC, Weismar C, editors. Leitlinien für Diagnostik und Therapie in der Neurologie. Stuttgart: Thieme Verlag; 2012.
19. Strzelczyk A, Ansorge S, Hapfelmeier J, Bonthapally V, Erder MH, Rosenow F. Costs, length of stay, and mortality of super-refractory status epilepticus: a population-based study from Germany. Epilepsia. 2017;58(9):1533–41.
20. Neligan A, Noyce AJ, Gosavi TD, Shorvon SD, Kohler S, Walker MC. Change in mortality of generalized convulsive status epilepticus in high-income countries over time: a systematic review and meta-analysis. JAMA Neurol. 2019;76(8):897–905.
21. Lowenstein DH, Aldredge BK. Status epilepticus at an urban public hospital in the 1980s. Neurology. 1993;43(3 Pt 1):483–8.
22. Aldredge BK, Gelb AM, Isaacs SM, Corry MD, Allen F, Ulrich S, et al. A comparison of lorazepam, diazepam, and placebo for the treatment of out-of-hospital status epilepticus. N Engl J Med. 2001;345(9):631–7.
23. Sathe AG, Underwood E, Coles LD, Eljm J, Silbergelit R, Chamberlain JM, et al. Patterns of benzodiazepine underdosing in the established status epilepticus treatment trial. Epilepsia. 2021:62(3):795–806.
24. Kellinghaus C, Rossetti AO, Trinka T, Lang N, May TW, Unterberger J, et al. Factors predicting cessation of status epilepticus in clinical practice: Data from a prospective observational registry (SENSE). Ann Neurol. 2019;85(3):421–32.
25. Willems LM, Bauer S, Jahnke V, Voss M, Rosenow F, Strzelczyk A. Therapeutic options for patients with refractory status epilepticus in palliative settings or with a limitation of life-sustaining therapies: a systematic review. CNS Drugs. 2020;34(8):801–26.
26. Haut SR. Seizure clusters: characteristics and treatment. Curr Opin Neurol. 2015;28(2):143–50.
27. Martinez C, Sullivan T, Hauser WA. Prevalence of acute repetitive seizures (ARS) in the United Kingdom. Epilepsy Res. 2009;87(2–3):137–43.
28. Dreifuss FE, Rosman NP, Cloyd JC, Pellock JM, Kuzniecky RI, Lo WD, et al. A comparison of rectal diazepam gel and placebo for acute repetitive seizures. N Engl J Med. 1998;338(26):1869–75.
29. Cereghino JJ, Mitchell WG, Murphy J, Kriell RL, Rosenfeld WE, Tretvathan E. Treating repetitive seizures with a rectal diazepam formulation: a randomized study. The North American Diastat Study Group. Neurology. 1998;51(5):1274–82.
30. Rose AB, McCabe PH, Gilliam FG, Smith BJ, Boggs JG, Ficker DM, et al. Occurrence of seizure clusters and status epilepticus during inpatient video-EEG monitoring. Neurology. 2003;60(6):975–8.
31. Haut SR, Lipton RB, LeValley AJ, Hall CB, Shinnar S. Identifying seizure clusters in patients with epilepsy. Neurology. 2005;65(8):1313–5.
32. Di Gennaro G, Picardi A, Sparano A, Mascia A, Meldolesi GN, Grammoldo LG, et al. Seizure clusters and adverse events during pre-surgical video-EEG monitoring with a slow anti-epileptic drug (AED) taper. Clin Neurophysiol. 2012;123(3):486–8.
33. Herzog AG, Fyre CA. Progesterone Trial Study G. Allopregnanolone levels and seizure frequency in progesterone-treated women with epilepsy. Neurology. 2014;83(4):345–8.
34. Maguire MI, Nevitt SJ. Treatments for seizures in catamenial (menstrual-related) epilepsy. Cochrane Database Syst Rev. 2019;10:13225.
35. Ferastraaru V, Goldenholz DM, Chiang S, Moss R, Theodore WH, Haut SR. Characteristics of large patient-reported
outcomes: where can one million seizures get us? Epilepsia Open. 2018;3(3):364–73.
36. Goldenholz DM, Rakesh K, Kapur K, Gainza-Lein M, Hodgeman R, Moss R, et al. Different as night and day: patterns of isolated seizures, clusters, and status epilepticus. Epilepsia. 2018;59(5):e73–7.
37. Möddel G, Kellinghaus C, Strzelczyk A. Initial treatment of status epilepticus. Z Epileptol. 2018;81:245–9.
38. Glauer T, Shinnar S, Gloss D, Alldredge B, Arya R, Bainbridge J, et al. Evidence-based guideline: Treatment of convulsive status epilepticus in children and adults: Report of the guideline committee of the American Epilepsy Society. Epilepsy Curr. 2016;16(1):48–61.
39. Greenblatt DJ, Divoll M, Harnatz JS, Shader RI. Pharmacokinetic comparison of sublingual lorazepam with intravenous, intramuscular, and oral lorazepam. J PharmSci. 1982;71(2):248–52.
40. Treiman DM. Pharmacokinetics and clinical use of benzodiazepine in the management of status epilepticus. Epilepsia. 1989;30(Suppl 2):S4-10.
41. Ameer B, Greenblatt DJ. Lorazepam: a review of its clinical pharmacological properties and therapeutic uses. Drugs. 1981;21(3):162–200.
42. Greenblatt DJ. Clinical pharmacokinetics of oxazepam and lorazepam. Clin Pharmacokinet. 1981;6(2):89–105.
43. Arya R, Gulati S, Kabra M, Sahu JK, Kalra V. Intranasal versus intravenous lorazepam for control of acute seizures in children: a randomized open-label study. Epilepsia. 2011;52(4):788–93.
44. Waltregny A, Dargent J. Preliminary study of parenteral lorazepam in status epilepticus. Acta Neurol Belg. 1975;75(5):219–29.
45. Walker JE, Homan RW, Vasko MR, Crawford IL, Bell RD, Tasker WG. Lorazepam in status epilepticus. Ann Neurol. 1979;6(3):207–13.
46. Leppik IE, Derivan AT, Homan RW, Walker J, Ramsay RE, Patric B. Double-blind study of lorazepam and diazepam in status epilepticus. JAMA. 1983;249(11):1452–4.
47. Treiman DM, Meyers PD, Walton NY, Collins JF, Colling C, Rowan AJ, et al. A comparison of four treatments for generalized convulsive status epilepticus. Veterans Affairs Status Epilepticus Cooperative Study Group. N Engl J Med. 1998;339(12):792–8.
48. Silberglett R, Durkalvis V, Lowenstein D, Conwit R, Pancholi A, Palesch Y, et al. Intramuscular versus intravenous therapy for prehospital status epilepticus. N Engl J Med. 2012;366(7):591–600.
49. Qureshi A, Wassmer E, Davies P, Berry K, Whitehouse WP. Comparative audit of intravenous lorazepam and diazepam in the emergency treatment of convulsive status epilepticus in children. Seizure. 2002;11(3):141–4.
50. Chamberlain JM, Okada P, Holsti M, Mahajan P, Brown KM, Vance C, et al. Lorazepam vs diazepam for paediatric status epilepticus: a randomized clinical trial. JAMA. 2014;311(16):1652–60.
51. Appleton R, Sweeney A, Choonara I, Robson J, Molyneux E. Lorazepam versus diazepam in the acute treatment of epileptic seizures and status epilepticus. Dev Med Child Neurol. 1995;37(8):682–8.
52. Welch RD, Nicholas K, Durkalvis-Mauldin VL, Lowenstein DH, Conwit R, Mahajan PV, et al. Intramuscular midazolam versus intravenous lorazepam for the prehospital treatment of status epilepticus in the paediatric population. Epilepsia. 2015;56(2):254–62.
53. Alvarez V, Lee JW, Dri slane FW, Westover MB, Novy J, Dworetzky BA, et al. Practice variability and efficacy of clonazepam, lorazepam, and midazolam in status epilepticus: A multicentre comparison. Epilepsia. 2015;56(8):1275–85.
54. Nordt SP, Clark RF. Midazolam: a review of therapeutic uses and toxicity. J Emerg Med. 1997;15(3):357–65.
55. Agency EM. Buccolam: EPAR - Product Information. European Medicines Agency.
56. Drug Information. FDA Label & American Society of Health-System Pharmacists. 2014.
57. Haschke M, Suter K, Hofmann S, Witschi R, Frohlich J, Imanidis G, et al. Pharmacokinetics and pharmacodynamics of nasally delivered midazolam. Br J Clin Pharmacol. 2010;69(6):607–16.
58. Knoester PD, Jonker DM, Van Der Hoeven RTM, Vermeij TAC, Edebroek PM, Brekelmans GJ, et al. Pharmacokinetics and pharmacodynamics of midazolam administered as a concentrated intranasal spray. A study in healthy volunteers. Br J Clin Pharmacol. 2002;53(5):501–7.
59. Wermeling DP, Record KA, Archer SM, Rudy AC. A pharmacokinetic and pharmacodynamic study, in healthy volunteers, of a rapidly absorbed intranasal midazolam formulation. Epilepsy Res. 2009;83(2–3):124–32.
60. Wermeling DP, Record KA, Kelly TH, Archer SM, Clinic T, Rudy AC. Pharmacokinetics and pharmacodynamics of a new intranasal midazolam formulation in healthy volunteers. Anesth Analg. 2006;103(2):344–9.
61. FDA Label Midazolam Injection. US Food and Drug Administration.
62. FDA Label NAYZILAM. US Food and Drug Administration.
63. Ulgey A, Aksu R, Bicer C. Nasal and buccal treatment of midazolam in epileptic seizures in paediatrics. Clin Med Insights Pediatr. 2012;6:51–60.
64. Prescribing information for NAYZILAM. US Food and Drug Administration. 2019; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211321Orig1s000lbl.pdf Reference ID: 443479; accessed on 5 July 2020.
65. Freilich ER. Clinical Review NDA 211321 Nayzilam (Intranasal midazolam). Center for Drug Evaluation and Research, US Food and Drug Administration. 2017; https://www.accessdata.fda.gov/drugsatfda_docs/nda/2019/211321Orig1s000MedR.pdf; accessed on 26 June 2020.
66. Kay L, Merkel N, von Blomberg A, Willems LM, Bauer S, Reif PS, et al. Intranasal midazolam as first-line inpatient hospital treatment for status epilepticus: a pharmaco-EEG cohort study. Ann Clin Transl Neuro. 2019;6(12):2413–25.
67. Kay L, Reif PS, Belke M, Bauer S, Frund D, Knake S, et al. Intranasal midazolam during presurgical epilepsy monitoring is well tolerated, delays seizure recurrence, and protects from generalized tonic-clonic seizures. Epilepsia. 2015;56(9):1408–14.
68. von Blomberg A, Kay L, Knake S, Fuest S, Zollner JP, Reif PS, et al. Efficacy, tolerability, and safety of concentrated intranasal midazolam spray as emergency medication in epilepsy patients during video-EEG monitoring. CNS Drugs. 2020;34(5):545–53.
69. Ulvi H, Yoldas T, Münge B, Yigit R. Continuous infusion of midazolam in the treatment of refractory generalized convulsive status epilepticus. Neurof. 2002;23(4):177–82.
70. Prasad A, Worrall BB, Bertram EH, Bleck TP. Propofol and midazolam in the treatment of refractory status epilepticus. Epilepsia. 2001;42(3):380–6.
71. Singh S, Murthy A, Singh P, Jayashree. Continuous midazolam versus diazepam infusion for refractory convulsive status epilepticus. J Child Neurol. 2002;17(2):106–10.
72. Chamberlain JM, Altiere MA, Futterman C, Young GM, Ochsen schlager DW, Waismann Y. A prospective, randomized study comparing intramuscular midazolam with intravenous diazepam for the treatment of seizures in children. Pediatr Emerg Care. 1997;13(2):92–4.
73. Galdames-Contreras D, Carrasco-Poblete E, Aguiler-Oliveras L, Fabrés-Oyarzo L, Galdames-Poblete D. Intramuscular midazolam in the initial treatment of status epilepticus. Rev Neurolog. 2006;42(6):332–5.
74. Momen AA, Azizi Malamiri R, Nikkhah A, Safari M, Fayzie A, Riahi K, et al. Efficacy and safety of intramuscular midazolam versus rectal diazepam in controlling status epilepticus in children. Eur J Paediatr Neurol. 2015;19(2):149–54.
75. Scott RC, Besag FMC, Neville BGR. Buccal midazolam and rectal diazepam for treatment of prolonged seizures in childhood and adolescence: a randomised trial. Lancet. 1999;353(9153):623–6.
76. Kutlu NO, Dogrul M, Yakinci C, Soylu H. Buccal midazolam for treatment of prolonged seizures in children. Brain Develop. 2003;25(4):275–8.
77. Nakken KO, Lossius MI. Buccal midazolam or rectal diazepam versus intravenous diazepam for treatment of prolonged seizures in adult patients. Eur J Paediatr Neurol. 2015;19(2):149–54.
78. Hardmeier M, Zimmermann R, Rüegg S, Pflüger M, Deuster P, et al. Intra-nasal midazolam: pharmacokinetics and pharmacodynamics assessed by quantitative EEG in healthy volunteers. Clin Pharmacol Ther. 2012;91(5):856–62.
79. Detyeniecki K, Van Ess PJ, Sequeira DJ, Whelless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters—a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797–808.
80. Whelless JW, Meng TC, Van Ess PJ, Detyeniecki K, Sequeira DJ, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters: An open-label extension trial. Epilepsia. 2019;60(9):1809–19.
81. Mahmoudian T, Mohammad MZ. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures: a phase I, randomized, open-label, single-dose, crossover, single-centre study. Drug Sci Test. 2011;31(8):585–97.
82. Lahat E, Goldman M, Barr J, Bristitzer T, Berkovich M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: Prospective randomised study. Brit Med J. 2000;321(7253):83–6.
83. De Haan GJ, Van Der Geest P, Doelman G, Bertram E, Edelbroek P. A comparison of midazolam nasal spray and diazepam rectal solution for the residential treatment of seizure exacerbations. Epilepsia. 2010;51(3):478–82.
84. Owusu KA, Dhakar MB, Bautista C, Mc Kinney D, Coutugno S, Sukumar N, et al. Comparison of intranasal midazolam versus intravenous lorazepam for seizure termination and prevention of seizure clusters in the adult epilepsy monitoring unit. Epilepsy Behav. 2019;98(Pt A):161–7.
85. Sutter R, Kaplan PW. Transanal revolution? The promise of diazepam as a new anticonvulsant. Clin Drug Invest. 2011;31(8):585–97.
86. Henney HR 3rd, Sperling MR, Rabinowicz AL, Carreon JA, Bream G, Carrazana EJ. Assessment of pharmacokinetics and tolerability of intranasal diazepam relative to rectal gel in healthy adults. Epilepsy Res. 2014;108(7):1204–11.
87. Abou-Khalil B, Whelless J, Rogn J, Wolter KD, Pixton GC, Shukla RB, et al. A double-blind, randomized, placebo-controlled trial of a diazepam auto-injector administered by caregivers to patients with epilepsy who require intermittent intervention for acute repetitive seizures. Epilepsia. 2013;54(11):1968–76.
88. Rogn J, Whelless J, Abou-Khalil B, Wolter KD, Pixton GC, Sherman NA, et al. Safety and effectiveness of long-term treatment with diazepam auto-injector administered by caregivers in an outpatient setting for the treatment of acute repetitive seizures. Epilepsia. 2014;55(9):1444–51.
89. Cereghino JJ, Cloyd JC, Kuzniecky RI. North American Diast Study G Rectal diazepam gel for treatment of acute repetitive seizures in adults. Arch Neurol. 2002;59(12):1915–20.
90. Pellock JM. Treatment of seizures and epilepsy in children and adolescents. Neurology. 1998;51(4 Suppl 4):S8-14.
91. Fakhoury T, Chumley A, Bensalem-Owen M. Effectiveness of diazepam rectal gel in adults with acute repetitive seizures and prolonged seizures: a single-centre experience. Epilepsia Behav. 2007;11(3):357–60.
92. Remy C, Jourdeil N, Villemain D, Favel P, Gontin P. Intrarectal diazepam in epileptic adults. Epilepsia. 1992;33(2):535–8.
93. Mitchell WG, Conry JA, Crumrine PK, Kriel RL, Cereghino JJ, Groves L, et al. An open-label study of repeated use of diazepam rectal gel (Diastat) for episodes of acute breakthrough seizures and clusters: safety, efficacy, and tolerance North American Diastat Group. Epilepsia. 1999;40(11):1610–7.
94. Vozeh S. Pharmacokinetic of benzodiazepines in old age. Schweiz Med Wochenschr. 1981;111(47):1789–93.
95. Hooper WD, Dickinson RG, Dunstan PR, Pendlebury SC, Ednie MJ. Oxcarbazepine: preliminary clinical and pharmacokinetic studies on a new anticonvulsant. Clin Exp Neurol. 1987:24:105–12.
96. Agarwal SK, Kriel RL, Brundage RC, Ivaturi VD, Cloyd JC. A pilot study assessing the bioavailability and pharmacokinetics of diazepam after intranasal and intravenous administration in healthy volunteers. Epilepsy Res. 2013;105(3):362–7.
97. Gizurason S, Gudbrandsson FK, Jonsson H, Bechgaard E. Intranasal administration of diazepam aiming at the treatment of acute seizures: clinical trials in healthy volunteers. Biol Pharm Bull. 1999;22(4):425–7.
98. Ivaturi VD, Riss JR, Kriel RL, Siegel RA, Cloyd JC. Bioavailability and tolerability of intranasal diazepam in healthy adult volunteers. Epilepsy Res. 2009;84(2–3):120–6.
99. Ivaturi VD, Riss JR, Kriel RL, Cloyd JC. Pharmacokinetics and tolerability of intranasal diazepam and midazolam in healthy adult volunteers. Acta Neurol Scand. 2009;120(5):353–7.
111. Smith BT, Masotti RE. Intravenous diazepam in the treatment of prolonged seizure activity in neonates and infants. Dev Med Child Neurol. 1971;13(5):630–4.

112. Kriel RL, Cloyd JC, Pellock JM, Mitchell WG, Cereghino JJ, Rosman NP. Rectal diazepam gel for treatment of acute repetitive seizures. The North American Diastat Study Group. Pediatr Neurol. 1999;20(4):282–8.

113. Singh S, Banerjee S, Singh P. Refractory status epilepticus in children: role of continuous diazepam infusion. J Child Neurol. 1998;13(1):23–6.

114. Henriksen PB. Acute treatment of epileptic seizures with diazepamum (Valium). Acta Neurol Scand. 1967;43(S31):168–9.

115. Hoppu K, Santavuori P. Intranasal midazolam versus diazepamum (Valium). Acta Neurol Scand. 1967;43(S31):168–9.

116. Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam and rectal diazepam for the treatment of prolonged seizures in children. Acta Paediatr Scand. 1981;70(3):369–72.

117. Chen WB, Gao R, Su YY, Zhao JW, Zhang YZ, Wang L, et al. Valproate versus diazepam for generalized convulsive status epilepticus: a pilot study. Eur J Neurol. 2011;18(12):1391–6.

118. Mehta V, Singh P, Singh S. Intravenous sodium valproate versus diazepam infusion for the control of refractory status epilepticus in children: a randomized controlled trial. J Child Neurol. 2007;22(10):1191–7.

119. Singh S, Murthy A, Singh P, Jayashree M. Continuous midazolam versus diazepam infusion for refractory status epilepticus. J Child Neurol. 2002;17(2):106–10.

120. Tang RH, Zhou JB. A control study on the treatment of acute seizures with midazolam and diazepam in children. Zhongguo Dang Dai Er Ke Za Zhi. 2010;12(7):530–2.

121. Gathwala G, Goel M, Singh J, Mittal K. Intravenous midazolam, lorazepam and midazolam lorazepam in acute seizure control. Indian J Pediatr. 2012;79(3):327–32.

122. Sreenath TG, Gupta P, Sharma KK, Krishnamurthy S. Lorazepam versus diazepam-phenytoin combination in the treatment of convulsive status epilepticus in children: a randomized controlled trial. Eur J Paediatr Neurol. 2010;14(2):162–8.

123. Shaner DM, McCurdy SA, Herring MO, Gabor AJ. Treatment of status epilepticus: a prospective comparison of diazepam and phenytoin versus phenobarbital and optional phenytoin. Neurology. 1988;38(2):202–7.

124. Shah I, Deshmukh CT. Intramuscular midazolam versus intravenous diazepam for acute seizures. Indian J Pediatr. 2005;72(8):667–70.

125. Portela JL, Garcia PC, Piva JP, Barcelos A, Bruno F, Branco R, et al. Intramuscular midazolam versus intravenous diazepam for treatment of seizures in the paediatric emergency department: a randomized clinical trial. Med Intensiva. 2015;39(3):160–6.

126. Lahat E, Goldman M, Barr J, Bistritzer T, Berkovitch M. Comparison of intranasal midazolam with intravenous diazepam for treating febrile seizures in children: prospective randomised study. BMJ. 2000;321(7253):83–6.

127. Mahmoudian T, Zadeh MM. Comparison of intranasal midazolam with intravenous diazepam for treating acute seizures in children. Epilepsy Behav. 2004;5(2):253–5.

128. Javadzadeh M, Sheibani K, Hashemieh M, Saneifard H. Intranasal midazolam compared with intravenous diazepam in patients suffering from acute seizure: a randomized clinical trial. Iran J Pediatr. 2012;22(1):1–8.

129. Talukdar B, Chakrabarty B. Efficacy of buccal midazolam compared to intravenous diazepam in controlling convulsions in children: a randomized controlled trial. Brain Dev. 2009;31(10):744–9.

130. Tonekaboni SH, Shamsabadi FM, Anvari SS, Mazrooei A, Ghofrani M. A comparison of buccal midazolam and intravenous diazepam for the acute treatment of seizures in children. Iran J Pediatr. 2012;22(3):303–8.

131. Mittal P, Manohar R, Rawat AK. Comparative study of intranasal midazolam and intravenous diazepam sedation for procedures and seizures. Indian J Pediatr. 2006;73(11):975–8.

132. Mipimbaa A, Ndegezi G, Stuedke S, Rosenthal PJ, Byarugaba J. Comparison of buccal midazolam with rectal diazepam in the treatment of prolonged seizures in Ugandan children: a randomized clinical trial. Pediatrics. 2008;121(1):e58–64.

133. Ashrafi MR, Khoroshoshi N, Karimi P, Malamiri RA, Bavarian B, Zarch AV, et al. Efficacy and usability of buccal midazolam in controlling acute prolonged convulsive seizures in children. Eur J Paediatr Neurol. 2010;14(5):434–8.

134. Baysun S, Aydin OF, Atmaca E, Gurur YK. A comparison of buccal midazolam and rectal diazepam for the acute treatment of seizures. Clin Pediatr (Phila). 2005;44(9):771–6.

135. Fisgin T, Gurur Y, Tezic T, Senbil N, Zorlu P, Okuyaz C, et al. Effects of intranasal midazolam and rectal diazepam on acute convulsions in children: prospective randomized study. J Child Neurol. 2002;17(2):123–6.

136. Bhattacharyya M, Kalra V, Gulati S. Intranasal midazolam vs rectal diazepam in acute childhood seizures. Pediatr Neurol. 2006;34(5):355–9.

137. Trajano M, Sanchez B, Lukhan M, Salonga A. P018WE40 Buccal midazolam compared to rectal diazepam and intravenous midazolam as emergent treatment of acute seizures in children: preliminary study. J Neurol Sci. 2009;255.

138. Malu CK, Kahamba DM, Walker TD, Mukampunga C, Musalu EM, Kokolomani J, et al. Efficacy of sublingual lorazepam versus intrarectal diazepam for prolonged convulsions in Sub-Saharan Africa. J Child Neurol. 2014;29(7):895–902.

139. Sirsi D. Is intranasal midazolam better than rectal diazepam for home management of acute seizures? Arch Neurol. 2011;68(1):120–1.

140. Chamberlain DB, Chamberlain JM. Making sense of a negative clinical trial result: a bayesian analysis of a clinical trial of lorazepam and diazepam for pediatric status epilepticus. Ann Emerg Med. 2017;69(1):117–24.

141. Meierkord H, Boon P, Engelsen B, Gocke K, Shorvon S, Tinuper P, et al. EFNS guideline on the management of status epilepticus in adults. Eur J Neurol. 2010;17(3):348–55.

142. Congdon PJ, Forsythe WI. Intravenous clonazepam in the treatment of status epilepticus in children. Epilepsia. 1980;21(1):97–102.

143. Gastaut H, Courjon J, Poire R, Weber M. Treatment of status epilepticus with a new benzodiazepine more active than diazepam. Epilepsia. 1971;12(3):197–214.

144. Navarro V, Dagron C, Elie C, Lambaut L, Demeret S, Urien S, et al. Prehospital treatment with levetiracetam plus clonazepam or placebo plus clonazepam in status epilepticus (SAMUKeppa): a randomised, double-blind, phase 3 trial. Lancet Neurol. 2016;15(1):47–55.

145. Pinder RM, Brogden RN, Speight TM, Avery GS. Clonazepam: a review of its pharmacological properties and therapeutic efficacy in epilepsy. Drugs. 1976;12(5):321–61.

146. Rantsch K, Walter U, Wittstock M, Benecke R, Rosche J. Treatment and course of different subtypes of status epilepticus. Epilepsy Res. 2013;107(1–2):156–62.

147. Singh AN, Le Morvan P. Treatment of status epilepticus with intravenous clonazepam. Prog Neuropsychopharmacol Biol Psychiatry. 1982;6(4–6):539–42.

148. Sorel L, Meehler L, Harmant J. Comparative trial of intravenous lorazepam and clonazepam in status epilepticus. Clin Ther. 1981;4(4):326–36.

149. Troester MM, Hastritter EV, Ng YT. Dissolving oral clonazepam wafers in the acute treatment of prolonged seizures. J Child Neurol. 2010;25(12):1468–72.
149. Abdel-Bar HM, Abdel-Reheem AY, Awad GA, Mortada ND. Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. J Pharm Pharm Sci. 2013;16(3):456–69.

150. Rylance GW, Poulton J, Cherry RC, Cullen RE. Plasma concentrations of clonazepam after single rectal administration. Arch Dis Child. 1986;61(2):186–8.

151. Crevoisier C, Delisle MC, Joseph I, Foletti G. Comparative single-dose pharmacokinetics of clonazepam following intravenous, intramuscular and oral administration to healthy volunteers. Eur Neurol. 2003;49(3):173–7.

152. Sakata O, Onishi H, Machida Y. Clonazepam oral droplets for the treatment of acute epileptic seizures. Drug Dev Ind Pharm. 2008;34(12):1376–80.

153. Greenblatt DJ, Blaskovich PD, Nuwayser ES, Harmatz JS, Chen M, Houser MM, et al. Benzodiazepine concentrations in brain involved in clonazepam metabolism. Fundam Clin Pharmacol. 2005;45(11):1288–93.

154. Roche. KLONOPIN TABLETS (clonazepam), KLONOPIN WAFERS (clonazepam orally disintegrating tablets). https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/017533s005lbl.pdf.

155. American College of Obstetricians and Gynecologists. Obstetric anesthesia. ACOG Committee Opinion No. 20648. Obstet Gynecol. 2011;118(2):572–5.

156. Ait-Daoud N, Hamby AS, Sharma S, Blevins D. A review of alprazolam use, misuse, and withdrawal. J Addict Med. 2018;12(1):4–10.

157. Smith RB, Kroboth PD, Vanderlught JT, Phillips JP, Juhi RP. Pharmacokinetics and pharmacodynamics of alprazolam after oral and IV administration. Psychopharmacology. 1984;84(4):452–6.

158. Huybrechts I. The pharmacology of alprazolam: a review. Clin Ther. 1991;13(1):100–17.

159. FDA. XANAX® - FDA label. Reference ID: 3004871: Food And Drug Administration (FDA); 2011.

160. Anderson GD. Children versus adults: pharmacokinetic and adverse-effect differences. Epilepsia. 2002;43(3):53–9.

161. Morselli PL, Principi N, Tognoni G, Reali E, Belvedere G, Standen SM, et al. Diazepam elimination in premature and full term infants, and children. J Perinat Med. 1973;1(2):133–41.

162. Blumer JL. Clinical pharmacology of midazolam in infants and children. Clin Pharmacokinet. 1998;35(1):37–47.

163. Gonzalez D, Chamberlain JM, Guptill JT, Cohen-Wolkowiez M, Harper B, Zhao J, et al. Population pharmacokinetics and exploratory pharmacodynamics of lorazepam in pediatric status epilepticus. Clin Pharmacokinet. 2017;56(8):941–51.

164. Chamberlain JM, Capparelli EV, Brown KM, Vance CW, Lillis K, Mahajan F, et al. Pharmacokinetics of intravenous lorazepam in paediatric patients with and without status epilepticus. J Pediatr. 2012;160(4):667–72.

165. European Medicines Agency. European Medicines Agency Committee for Medicinal Products for Human Use assessment report for Buccolam® (buccal midazolam); 2011.

166. Garnock-Jones KP. Oromucosal midazolam: a review of its use in paediatric patients with prolonged acute convulsive seizures. Paediatr Drugs. 2012;14(4):251–61.

167. U.S. Food & Drug Administration. FDA-approved drugs - diazepam. 2021 [cited; Available from: https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&varApplNo=020648.

168. Rogalski R, Rogalski A. Benzodiazepine selection in the management of status epilepticus: a review. Adv Emerg Nurs J. 2015;37(2):83–94.

169. Trinka E, Holter J, Leitinger M, Brigo F. Pharmacotherapy for status epilepticus. Drugs. 2015;75(13):1499–521.

170. Der-Nigogossian C, Rubinos C, Alkhachroum A, Claassen J. Status epilepticus—time is brain and treatment considerations. Curr Opin Crit Care. 2019;25(6):638–46.

171. Wermeling DP, Miller JL, Archer SM, Manaligod JM, Ruddy AC. Bioavailability and pharmacokinetics of lorazepam after intranasal, intravenous, and intramuscular administration. J Clin Pharmaco. 2001;41(11):1225–31.

172. Lau CE, Ma F, Wang Y, Smith C. Pharmacokinetics and bioavailability of midazolam after intravenous, subcutaneous, intraperitoneal and oral administration under a chronic food-limited regimen: relating DRL performance to pharmacokinetics. Psychopharmacology. 1996;126(3):241–8.

173. Shangguan Y, Liao H, Wang X. Clonazepam in the treatment of status epilepticus. Expert Rev Neurother. 2015;15(7):733–40.

174. Horgan RE, Gidal BE, Koplowitz B, Koplowitz LP, Lowenthal RE, Carrzana E. Bioavailability and safety of diazepam intranasal solution compared to oral and rectal diazepam in healthy volunteers. Epilepsia. 2020;61(3):455–64.

175. Ahmad S, Ellis JC, Kamwendo H, Molyneux E. Efficacy and safety of intranasal lorazepam versus intramuscular paraldehyde for protracted convulsions in children: an open randomised trial. Lancet. 2006;367(9522):1591–7.
188. Jeannet PY, Roulet E, Maeder-Ingvar M, Gehri M, Jutzi A, Deonna T. Home and hospital treatment of acute seizures in children with nasal midazolam. Eur J Paediatr Neurol. 1999;3(2):73–7.
189. Kazmi A, Abbas G, Khurshid A, Sahr S, Malhi T, Hanif M, et al. A comparison of intravenous midazolam and diazepam in management of status epilepticus in children. J Pak Med Assoc. 2020;2:1–13.
190. Kutlu NO, Dogrul M, Yakinci C, Soylu H. Buccal midazolam for treatment of prolonged seizures in children. Brain Dev. 2003;25(4):275–8.
191. Griffith PA, Karp HR. Lorazepam in therapy for status epilepticus. Ann Neurol. 1980;7(5):493.
192. Lacey DJ, Singer WD, Horwitz SJ, Gilmore H. Lorazepam therapy of status epilepticus in children and adolescents. J Pediatr. 1986;108(5 Pt 1):771–4.
193. Crawford TO, Mitchell WG, Snodgrass SR. Lorazepam in childhood status epilepticus and serial seizures: effectiveness and tachyphylaxis. Neurology. 1987;37(2):190–5.
194. Giang DW, McBride MC. Lorazepam versus diazepam for the treatment of status epilepticus. Pediatr Neurol. 1988;4(6):358–61.
195. Misra UK, Kalita J, Maurya PK. Levetiracetam versus lorazepam in status epilepticus: a randomized, open labeled pilot study. J Neurol. 2012;259(4):645–8.
196. Chin RF, Neville BG, Peckham C, Wade A, Bedford H, Scott RC. Treatment of community-onset, childhood convulsive status epilepticus: a prospective, population-based study. Lancet Neurol. 2008;7(8):696–703.
197. Detyeniecki K, Van Ess PJ, Sequeira DJ, Wheless JW, Meng TC, Pullman WE. Safety and efficacy of midazolam nasal spray in the outpatient treatment of patients with seizure clusters-a randomized, double-blind, placebo-controlled trial. Epilepsia. 2019;60(9):1797–808.
198. Gathwala G, Goel M, Singh J, Mittal K. Intravenous diazepam, midazolam and lorazepam in acute seizure control. Indian J Pediatr. 2012;79:327–32.
199. Bergamini L, Mutani R, Fariello R, Liboni W, Quattrocolo GL. Action du Ro 5/4023 dans le traitement des differentes formes d’epilepsie. Paper given at the Rivotril Symposium, Marseilles, France. 1972.
200. Bergamini L, Mutani R, Liboni W. Elektroenzephalographische und klinische Bewertung des neuen Benzodiazepin Ro 5/4023. EEG EMG. 1970;1:182–8.
201. Gimenez-Roldan S, Lopez Agreda J, Martin F. Un nuevo medicamento eficaz en el tratamiento del status epilepticus - Ro 5-4023. Med Clin (Barc). 1972;58(133).
202. Beck H, Tousche C. Traitement des etats de mal epileptiques par le clonazepam Sem Hop Paris. 1973;49(21).
203. Bladin PF. The use of clonazepam as an anticonvulsant—clinical evaluation. Med J Aust. 1973;1(14):683–8.
204. Ketz E, Bernoulli C, Siegfried J. Clinical and electroencephalographic trial with clonazepam (Ro 5–4023) with special regard to status epilepticus. Acta Neurol Scand Suppl. 1973;53:47–53.
205. Kruse R, Blankenhorn V. Clinical use and effect of Ro 5–4023 (clonazepam) in different forms of epileptic seizures. Acta Neurol Suppl. 1973;53:60–71.
206. Martin D, Hirt H. Clinical experience with clonazepam (Rivotril) in the treatment of epilepsies in infancy and childhood. Neuro-paediatrics. 1973;4:245–66.
207. Tridon P, Weber M. Conduite du traitement des etats de mal epileptiques par le Ro. Sem Hop Paris. 1973;49:29.